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Abstract 
Parkinson Disease (PD) is a progressive and debilitating neurodegenerative disease 
characterized by the inadequate function or the loss of dopamine-producing neurons in the 
human midbrain. PD has a complex etiology including aberrant protein inclusion, 
mitochondrial dysfunction, oxidative stress, and defects in protein trafficking, which may 
occur due to genetic or non-genetic factors. Recently identified PD causative genes can be 
evaluated in model organisms, through which pathophysiological interactions with 
previously discovered PD genes may be determined. A new gene associated with PD, 
UHRF1BP1L, has a putative role in mitochondrial dynamics and protein homeostasis, 
similar to several other well-established PD genes. I investigated CG34126, the only 
homologue of UHRF1BP1L in  Drosophila melanogaster, in an attempt to model PD using 
the UAS-GAL4 system of inducible gene expression in the dopaminergic neurons as well 
as during the development of the eye. In brief, RNAi-mediated knockdown of CG34126 
can reduce lifespan and locomotor ability over time, and the overexpression of CG34126 
directed by the Dopa decarboxylase (Ddc)-Gal4 transgene leads to reduced longevity and 
climbing ability throughout life. However, overexpression of CG34126 partially rescues 
the parkin-RNA-interference model of PD by increasing both longevity and locomotor 
ability over time. No neurodevelopmental defect was observed through a detailed biometric 
analysis of eye phenotypes, either from overexpression or knockdown of CG34126. As the 
altered ectopic expression of CG34126 can either positively or negatively influence ageing 
and locomotion, the consequences of altering UHRF1BP1L function in the fly contributes 
a better understanding of PD and general ageing mechanisms. 
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Introduction 
 
Parkinson Disease 
 
Parkinson Disease (PD) is the second most common chronic progressive 
neurodegenerative disorder with approximately a 2% probability of occurrence during a 
lifetime. It clinically manifests through uncontrolled tremor, muscular rigidity, 
bradykinesia, and postural instability coupled with several non-motor symptoms, such as 
cognitive impairment, autonomic complications, and psychiatric problems (Savitt et al., 
2006; Dorsey et al., 2007). Approximately 1% of  people may be affected by PD by the 
age of 65 years; this prevalence elevates to 4 to 5% of the population by the age of 85 years 
(Xiong et al., 2017). About 85% of people have forms of PD without a clearly identified 
inherited basis, while 5 to 10% of people with Parkinsonism have rare familiar or inherited 
conditions (Lesage & Brice, 2009). Both broad classes of PD originate from the progressive 
depletion and death of dopamine-producing nigrostriatal neurons in the substantia nigra 
pars compacta (SNpc) of the midbrain (Fanali et al., 2010) and axon terminals projecting 
to the dorsal striatum (Hornykiewicz, 1962). Alongside nigrostriatal dopaminergic 
degeneration, most of the non-dopaminergic symptoms of PD get more severe with 
advancement of age and progression of the disease. A distinctive neuropathological feature 
of PD is the presence of neuronal inclusions termed Lewy bodies (LB) and of Lewy 
neurites (LN) due to fibrillar aggregation of phosphorylated α-synuclein, ubiquitin, and 
other proteins concentrated in susceptible regions of the central nervous system (CNS) and 
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peripheral autonomic nervous system (Cavallarin et al., 2010; Forno, 1996; Lebouvier et 
al., 2010). Irregular secretion of neurotransmitters, in addition to dopamine, is linked to the  
motor and non-motor symptoms of PD etiology (Barone, 2010). At present, significant 
research efforts are involved in the deciphering of the genetic and molecular pathways of 
neurodegeneration, LB inclusion, and the ubiquitin-proteasome mechanism related to PD 
by the functional characterization of susceptible PD genes. 
 
 
Causative and associated genes of PD 
 
The analysis of the potential causes of PD indicates that the disease is a sporadic 
disorder largely due to a combination of environmental, toxic, and epidemiological factors. 
Therefore, a basic unified cause of PD has not been established as of yet. However, genes 
linked to PD have contributed to a better comprehension of the sporadic or idiopathic and 
the inherited forms of PD through epidemiologic studies (Dawson & Dawson, 2003). Since 
the discovery of the first PD gene PARK1/PARK4, which encodes the protein α-synuclein 
(Polymeropoulos et al., 1997), a considerable number of genes with variants that lead to 
susceptibility have been added to the list of PD causative genes. Genetic analysis, 
molecular identification and characterization, neuropathologic investigations, and novel 
experimental models of PD in both vertebrates and invertebrates illustrate that at least 16 
distinct gene loci are responsible for Mendelian forms of PD (Thomas & Beal, 2011). The 
research conducted into PD has found LRRK2 (Paisán-Ruı́z et al., 2004), UCHL1 (Leroy 
et al., 1998), HTRA2 (Satake et al., 2009), VPS35 (Zimprich et al., 2011) including SNCA 
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are autosomal dominant (AD) or gain-of-function form of PD genes. Autosomal recessive 
(AR) or loss-of-function mutant genes include parkin or park (Kitada et al., 1998), PINK1 
(Valente et al., 2004), Dj-1 (Bonifati et al., 2003), GBA (Aharon-Peretz, et al., 2004), 
ATP13A2 (Ramirez et al., 2006) and FBXO7 (Di Fonzo et al., 2009). Of the many candidate 
genes, the best studied include SNCA, parkin, PINK1, LRRK2, DJ1 and VPS35 (Kim & 
Alcalay, 2017). Either through loss-of-function or gain-of-function, these PD genes (Table 
1) are responsible for abnormal protein aggression (LB and LN), alteration of 
mitochondrial function, oxidative stress, autophagy, mitophagy, lysosomal and Golgi body 
protein trafficking, protein phosphorylation, and abnormal handling of misfolded proteins. 
(Krüger, 2004; Eriksen et al., 2005; Thomas & Beal, 2011; Kalinderi et al., 2016;). 
Studying these genes and the role they play in the progression of the disease has helped to 
elucidate common pathways in PD pathogenesis.  
 
Drosophila melanogaster as a model organism for neurodegenerative diseases 
 
Drosophila melanogaster, commonly known as the “fruit fly” has played an 
innovative and noteworthy pioneering role in biological research (Staveley, 2012). As a 
model organism, Drosophila melanogaster has been used for the study of animal 
development, behaviour, neurobiology, and human diseases and disorders, including 
Parkinson Disease. Easy to culture, with a short life cycle, a non-problematic breeding 
process, and a small genome size with small chromosome numbers fortify its place in the 
genetic study (Burdett & Vanden Heuvel, 2004). Although, there is a disparity between  
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Table 1: List of established genes responsible for familial forms of Parkinson Disease 
HGNC 
symbol  
Gene Inheritance 
 
Probable function References 
PARK1 
 
α-
synuclein/ 
SNCA 
EOPD AD and 
sporadic  
Presynaptic 
protein, Lewy 
body, lipid and 
vesicle dynamics 
(Polymeropolus 
et al.,1997) 
PARK2 
 
Parkin Juvenile and 
AR EOPD and 
sporadic  
Ubiquitin E3 
ligase, mitophagy 
(Kitada et al., 
1998) 
PARK3 Unknown LOPD AD  Unknown  
PARK4 SNCA EOPD AD Presynaptic 
protein, Lewy 
body, lipid and 
vesicle dynamics 
(Polymeropolus 
et al., 1997) 
PARK5 
 
UCH-L1 LOPD AD  Ubiquitin C-
terminal hydrolase 
(Leroy et al., 
1998) 
PARK6 
 
PINK1 AR EOPD  Mitochondrial 
kinase 
phosphorylates 
parkin 
(Valente et al., 
2004) 
PARK7 
 
DJ-1 AR EOPD   Oxidative stress, 
Chaperone, 
Antioxidant  
(Bonifati et al., 
2003) 
PARK8 
 
LRRK2 LOPD AD and 
sporadic  
Kinase signalling, 
cytoskeletal 
dynamics, protein 
translation 
(Paisán-Ruı́z et 
al., 2004) 
PARK9 
 
ATP13A2 Juvenile Kufor–
Rakeb 
syndrome, and 
EOPD AR 
Lysosomal 
dysregulation, 
autophagic flux 
reduction, and 
mitochondrial 
clearance. Putative 
involvement in the 
oxidative stress 
response. 
(Ramirez et al., 
2006; Tsunemi 
et al., 2014)  
PARK10 Unknown PD Risk Factor  Unknown  
PARK11 Unknown LOPD AD  IGF-1 signalling  
PARK12 Unknown PD Risk Factor  Unknown  
PARK13 
 
HTRA2 AD or risk 
factor 
Mitochondrial 
serine protease  
(Strauss et al., 
2005)  
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PARK14 
 
PLA2G6 Juvenile 
levodopa-
responsive 
dystonia-
parkinsonism 
AR 
Phospholipase 
enzyme. Mutations 
in PLA2G6 cause 
aberrant ER 
calcium signalling 
which may impede 
mitophagy and the 
oxidative stress 
response 
(Kinghorn et 
al., 2015; 
Strokin et al., 
2012)  
PARK15 
 
FBXO7 AR EOPD  Ubiquitin E3 
ligase, 
mitochondrial 
dysfunction 
(Di Fonzo et al., 
2009) 
PARK16 
 
RAB7L1 Classical PD 
Risk Factor 
Modify 
Intraneuronal 
Protein Sorting 
Vesicles dynamics, 
autophagy 
(MacLeod et 
al., 2013)  
PARK17 
 
VPS35 Classical PD 
AD 
Intraneuronal 
protein sorting 
(Zimprich et al., 
2011) 
PARK18 
 
EIF4G1 Classical PD 
AD 
Oxidative stress (Chartier-Harlin 
et al., 2011)  
PARK19 DNAJC6 
DnaJ heat 
shock 
protein 
Juvenile onset, 
atypical AR PD 
Encodes Auxilin, a 
member of the 
Hsp40 chaperone 
family. Works in 
tandem with 
SYNJ1to recycle 
synaptic vesicles. 
(Edvardson et 
al., 2012; 
Ohtsuka & 
Hata, 2000) 
PARK20 
 
SYNJ1 Juvenile onset, 
atypical AR PD 
Encodes 
synaptojanin-1, a 
phosphoinositide 
phosphatase. 
Works with 
DNAJC6 to recycle 
synaptic vesicles. 
(Quadri et al., 
2013) 
PARK21 
 
DNAJC13 LOPD AD Endosomal 
transport 
impairment 
(Vilariño-Güell 
et al., 2013) 
AR-Autosomal recessive, AD-Autosomal dominant, EO-Early onset, LO-Late onset, 
HGNC-HUGO gene nomenclature committee 
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human neuronal distribution and fly brains, both have neural function similarity. 
Compilation of Drosophila melanogaster and human genome sequence has revealed that 
Drosophila have an immensely conserved number of genes compared to human 
(Whitworth et al., 2006).  Drosophila melanogaster genome encodes 75% orthologues of 
human disease genes (Marsh et al., 2003). Moreover, it can be 80 to 90%, or more similar 
in conserved functional domains to human proteins. To construct a neurodegenerative 
disease model, Drosophila melanogaster is a perfect choice because it has a fully active 
nervous system with differentiation in vision, smell, muscular control, and memory like 
mammalian organisms. 
 
Modelling Parkinson Disease in Drosophila melanogaster 
 
Though the central nervous system of flies is smaller in size compared to higher 
vertebrates, more than 100,000 neurons mediated by neurotransmitter complexes are well 
conserved in humans. Approximately 200 dopaminergic neurons (DA) are involved in 
complex behaviour patterns of flies, such as fertility, developmental time, sleep, and motor 
control (Neckameyer, 1996; Pandey & Nichols, 2011; Van Swinderen & Andretic, 2011). 
Studies in this model organism have mapped out important dopaminergic genes whose 
modification lead to phenotypic expression like PD. Therefore, their mechanisms affect 
various influential etiologies of PD and highlighting potential treatment strategies (Feany 
& Bender, 2000). Irrespective of the affected human tissues, the homologues of human 
genetic disease loci demonstrate selective expression in the Drosophila tissues (Chintapalli  
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et al., 2007), and it is possible to control ectopic expressions of specific genes related to 
dopaminergic activity in various ways (overexpression or inhibition) by using the UAS-
GAL4 system in Drosophila (Phelps & Brand, 1998). GAL4 and UAS-target genes are 
maintained in distinct fly lines: directed expression and responder lines, respectively 
(Figure 1). The yeast transcriptional activator GAL4 of directed line, under promoter 
control, directs the transcription of a gene that resides downstream of the upstream 
activating sequence (UAS) of responder line and directs the expression of that particular 
gene in a specific tissue, such as eye, muscles, neuron or whole body in a time-specific 
manner. The target gene is silent in absence of GAL4.When crosses between flies are 
established, in the progeny the activator factor of GAL4 binds to the enhancer region of 
the target gene in UAS to induce transcription of the gene. Different types of tissue-specific 
GAL4 fly lines are utilized in PD modelling, including the motor neuron-specific promoter; 
D42, the predominately dopaminergic and other neurons-specific promoter; dopa 
decarboxylase (Ddc), the dopaminergic neuron-specific promoter; tyrosine hydroxylase 
(TH), and the eye-specific promoter; glass multiple reporter (GMR) (Feany & Bender, 
2000; Boto et al., 2014). This technique is widely used and convenient for selective 
expression or knockdown of specific genes in various lines of flies. 
The compound eye of an adult Drosophila melanogaster is composed of 
approximately 800 hexagonal visual units called ommatidia (Neriec & Desplan, 2016). 
Each ommatidium consists of eight photoreceptor neurons, and the total visual system 
contains about 150,000 neurons and glia cells (Chiang et al., 2011). Neurodegeneration 
can be examined by observing the ommatidium, inter-ommatidial bristles, eye shape,   
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Figure 1.  The GAL4-UAS directed expression system. 
Maintained in two distinct lines of flies, in the critical class of progeny the yeast derived 
transcriptional activator GAL4 of the directed expression line, under a tissue specific 
promoter control, binds to the upstream activating sequence or UAS of desired gene in 
responder line and drives the transcription of the target gene.   
  
disruption, ratio, and lobe, as the development and continued maintenance of all neurons 
are related to the functional structure of the adult eye. Analysis of altered eyes has cast a 
light into the field of cellular mechanisms, signalling transduction and transcription, cell 
proliferation, growth, and apoptosis (Kumar, 2012). Therefore, various types of neuronal 
gene expression in different tissues of  Drosophila melanogaster allows modelling of major 
aspects of PD. 
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Models of PD 
 
The α-synuclein model 
 
The α-synuclein (SNCA/PARK1/PARK4) is known as the first identified gene in 
rare and severe familial forms of PD pathology, which encodes a small and soluble 
presynaptic nerve terminal protein (Polymeropolus et al.,1997). This gene represents one 
of the most abundant protein components found in Lewy bodies, and it is believed to play 
an important role in the progression of PD by creating insoluble fibril depositions in the 
brain. While Drosophila melanogaster lacks a clear α-synuclein orthologue, expression of 
the wild human type and two mutant forms of α-synuclein, A30P and A53T are responsible 
for phenotypic features that model autosomal-dominant PD in flies. Additional SNCA 
triplication and duplication mutations, this model can reproduce similar key features of PD, 
such as, adult-onset degeneration and loss of DA neurons, retinal degeneration, aggregation 
of proteinaceous α-synuclein inclusions, and locomotor defects (Botella et al., 2009). In 
Drosophila, expression of both α-synuclein normal and mutant forms generate adult-onset 
degeneration of dopaminergic neurons, filamentous intraneuronal aggregation containing 
α-synuclein, and locomotor disorder. The Drosophila model thus recapitulates the essential 
features of PD, which makes it a powerful genetic approach to this disease (Feany & 
Bender, 2000). Auluck and colleagues (Auluck et al., 2002) argued that dopaminergic 
neuronal loss due to α-synuclein in flies could be prohibited by the overexpression of the 
chaperone protein Hsp70, thereby indicating the regulatory role of this chaperone in α-
synuclein toxicity. Another investigation showed that geldanamycin-treated flies had a 
reduced stress response to elevated chaperone activity, which ultimately protects against 
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α-synuclein induced neurotoxicity (Auluck et al., 2005). However, the whole mount 
immunohistochemistry analysis of α-synuclein fly models proved that there was no loss of 
dopaminergic neuronal cells in fly brains (Pesah  at el., 2004). Maybe some environmental 
factors influenced this experiment and more analysis is needed to justify and clarify this 
issue. ROS causes damage of intracellular components (lipids, proteins, and DNA in post-
mortem PD brain) and enhances apoptotic cell death, both of which are common in autopsy 
tissue from the brains of PD patients. In rat mutants, a model of SNCA showed that, mis-
folding of alpha-synuclein oligomers induced ROS and neuronal toxicity by production of 
aberrant free metal ions. (Deas et al., 2016). Overexpression of Rab1, the mammalian YPT1 
homologue, suppressed α-synuclein-induced dopaminergic neuron loss in animal models 
of PD (Cooper et al., 2006). Sirtuin 2 inhibited SIRT2 via interfering RNA, and rescued α-
synuclein toxicity and changed protein inclusion structure of α-synuclein in a cellular 
model of PD. This inhibitor protected against dopaminergic cell death both in vitro and in 
a Drosophila model of PD (Outeiro et al., 2007). Co-expression of park can suppress 
phenotypes caused by the expression of mutant α-synuclein, such as in the developing eye, 
where park reduces retinal degeneration. When co-expressed in the dopaminergic neurons, 
the ability to climb was improved in flies (Haywood & Staveley, 2006; van der Merwe at 
el., 2015). Further exploration of the interaction of α-synuclein with other proteins can 
open new therapeutic solutions of PD. These variations show the complexity of biological 
systems that are modified by α-synuclein, which plays an important role in elucidating 
intricate pathways of PD. 
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The parkin model 
The parkin gene encodes a cytosolic ubiquitin isopeptide E3 ligase that is 465 
amino acid residues in length; it contains an N-terminal ubiquitin‐like domain (Ubl), and 
four Zn‐coordinating really interesting new gene (RING)‐like domains: RING0, RING1, 
IBR (in-between RING), and RING2. (Shimura et al., 2000; Finney et al., 2003; Seirafi et 
al., 2015). RBR (RING‐between‐RING) domains of parkin are involved in substrate 
identification, binding ubiquitin interacting motif (UIM) domains, degradation of 
misfolded protein by ubiquitin proteasome system (UPS), and the regulation of cellular 
parkin levels of two functional sites (being the binding and catalytic sites). It ubiquitinates 
multiple numbers of cytosolic and outer mitochondrial membrane proteins upon 
mitochondrial depolarization. Parkin plays a central role in the cascade reaction, where E3 
ubiquitin‐ligating enzyme conjugates with E1 ubiquitin‐activating enzymes and E2 
ubiquitin‐conjugating enzymes of the ubiquitin proteasome system (UPS) to ubiquitinate 
misfolded or agglomerated proteins. These proteins later target impaired or unwanted 
proteins for degradation by the 26S proteasome (Kazlauskaite et al., 2014). More than 170 
pathogenic PD mutations have been determined throughout parkin domains, causing 
PARK2 protein loss of function for each of the individual domains (Pickrell & Youle, 
2015). The protein products of parkin promotes the UPS for the accumulation of impaired 
mitochondria which enhances toxic reactive oxygen species (ROS) and contributes to the 
degradation of dysfunctional mitochondria by autophagy and neuronal cell death in PD 
(Narendra et al., 2008; Chan et al., 2011; Ashrafi et al., 2014). Numerous studies over 
the years have proven that protein product of PINK1 and parkin follow the same 
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biochemical pathways to clear damaged mitochondria (Narendra et al., 2012). PINK1 acts 
upstream of parkin, which accumulates first on dysfunctional mitochondria. Then its kinase 
activity phosphorylates parkin (Kane et al., 2014). Upon activation by PINK1, parkin 
ubiquitinates the damaged mitochondria through the modification of numerous cytosolic 
and outer mitochondrial membrane (OMM) proteins such as Mitofusin or Miro to instigate 
the removal of mitochondria by mitophagy. In this pathway, the mitochondrial kinase 
PINK1 senses mitochondrial fidelity and recruits parkin selectively to mitochondria that 
lose membrane potential (Sauve et al., 2015; Pickrell & Youla,  2014). These two proteins 
function together in a mitochondrial quality control pathway whereby PINK1 accumulates 
on damaged mitochondria and activates parkin to induce mitophagy. 
Several mutations, such as point mutation and deletion are related to parkin 
(PARK2), have provided new insights into the survival of dopaminergic neurons in both 
sporadic and familial models of PD in Drosophila. Alongside degeneration and loss of DA 
neurons in the adult brain, these mutant flies exhibit apoptotic flight muscle degeneration 
and locomotor defects from mitochondrial dysfunction, hypersensitivity to reactive 
oxidation stress and environmental stress, reduced life span, male sterility, developmental 
delay, and decreases in cell count and size (Greene et al., 2003; Hattori & Mizuno, 2004; 
Pesah, .et al., 2005). Loss-of-function mutations in parkin produced high amounts of free 
radicals, possibly in high energy-dependent cell groups with reduced cell size (Pesah, et 
al., 2005). Loss-of-function mutations of the glutathione S-transferase S1 (GstS1) gene in 
flies display a degeneration of specific dopaminergic neurons in the brain but 
overexpression of GstS1 in DA neurons reduces neurodegeneration in parkin mutants 
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(Whitworth et al., 2005). The Pael receptor, a transmembrane polypeptide, interacts with 
parkin and leads to unfolded and accumulated protein-induced selective neuronal death in 
autosomal recessive juvenile Parkinsonism (Imai et al., 2001). Moreover, the 
overexpression of a human parkin mutant R275W in Drosophila resulted in an age-
dependent degeneration of specific DA neuronal clusters, concomitant locomotor deficits 
that were exacerbated with age, and mitochondrial abnormalities in the flight muscles. The 
above-mentioned defects caused by the expression of human R275W parkin are highly 
similar to those directed by the loss of parkin in park null flies (Wang et al., 2007). The 
findings of park mutants in flies are still going on and have reiterated the significance of 
this model organism in revealing the pathology of human PD.  
  
  
The PINK1 model 
The PINK1 gene encodes a 581 amino acid protein consisting of an N-terminal 
mitochondrial targeting motif and a conserved kinase domain (serine/threonine kinase) 
homologous to the Ca2+/calmodulin family (Valente et al., 2004). Several nonsense and 
missense mutations in PINK1 cause early onset autosomal recessive (EOAR) parkinsonism 
with atypical features to clinical presentations that differentiate from sporadic late-onset 
PD (Silvestri et al., 2005; Clarimón et al., 2006; Muqit et al., 2006;). A lack of PINK1 
genes results in an age-dependent loss of neuronal viability and increased sensitivity to 
oxidative stress and stress-induced mitochondrial apoptosis. Dysregulation of 
mitochondria is implicated due to the presence of lowered mitochondrial membrane 
potential (Wood-Kaczmar et al., 2008). PINK1 encodes serine-threonine kinase which 
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regulates a set of substrates prone to protein agglomeration and plays an important role in 
mitochondrial homeostasis. Both mitochondrial dysfunction and kinase pathways 
regulated by PINK1 play important roles in neurodegeneration. Drosophila PINK1 is found 
to localize in the mitochondrial membrane like human PINK1. The pathogenic role of 
PINK1 in maintaining mitochondrial integrity has established with mutational analysis of 
the Drosophila orthologue by transposon-mediated mutagenesis and RNAi. Loss of PINK1 
causes degeneration of apoptotic flight muscles, defective spermatid formation, DA 
neuronal death, locomotor deficits, and oxidative stress in flies (Greene, et al., 2003). These 
physical features are associated with defective mitochondrial morphology and disruptions, 
and share prominent phenotypic similarities with parkin (park) mutants. The  park protein 
product functions downstream of PINK1: its transgenic expression in flies markedly 
improved all PINK1 loss-of-function phenotypes, but not vice versa (Clark et al., 2006; 
Gandhi et al., 2006; Park et al., 2006; Banerjee et at., 2009). All of these observations 
support the notion that mitochondrial dysfunction is a vital contributing factor to DA 
neuron loss in patients with altered PINK1 function. 
 
The DJ-1 model 
DJ-1 belongs to the ThiJ/Pfpl protein superfamily and acts as a suppressor of PTEN 
function. DJ-1 encodes an 189 amino acid protein that is shown to have a functional domain 
resemblance to proteases, kinases and heat shock proteins (Thomas & Beal, 2011). This 
gene controls cell death and survival through multiple cellular functions. It acts as a redox-
sensitive molecular chaperone in an oxidative cytoplasmic environments, operates an 
15 
 
antioxidant action for ROS, stabilizes antioxidant transcriptional master regulator nuclear 
factor Nrf-2, transforms cells in cooperation with H-ras, and androgen receptor signalling 
(Da Costa, 2007;  Bonifati et al., 2003; Kim, R. H. et al., 2005; Menzies et al., 2005; Abou-
Sleiman et al., 2006). Mutations in the C-terminal helix of DJ-1 that alter antioxidant 
function have been identified in various PD patients which associated with autosomal 
EOPD (Bonifati et al., 2003; Tao & Tong, 2003). Drosophila melanogaster homologues 
of DJ-1 play critical roles in the survival of dopaminergic neurons and response to 
oxidative stress. Two homologues of DJ-1 in Drosophila are DJ-1α and DJ-1β, which 
show different results in the DJ-1 loss-of-function model. DJ-1β is expressed ubiquitously, 
while DJ-1α is expressed only in the male germline. Knockout of both homologues 
generates fertile flies with normal lifespan, but they are susceptible to environmental 
factors such as paraquat (1,1'-Dimethyl-4,4'-bipyridinium dichloride) and rotenone. These 
factors are related to PD in humans and the resultant loss of DJ-1β protein is responsible 
to increase oxidative stress (Meulener et al., 2005). Another experiment shows that loss-
of-function DJ-1β mutants increase the survival of dopaminergic neurons and resistance to 
the effect of paraquat stress, but are very susceptible to hydrogen peroxide treatment. 
Upregulation of DJ-1α expression in the brain of the DJ-1β mutant resulted in a 
compensatory effect for paraquet, rotenone, and hydrogen peroxide sensitivity (Menzies et 
al., 2005). RNA interference (RNAi) mediated inhibition of DJ-1α results in cellular 
aggregation of reactive oxygen species, acute sensitivity to oxidative stress, degeneration 
of dopaminergic neurons, and impairment of PI3K/Akt signalling (Yang et al., 2005). 
Expression of only the PTEN transgene in the eye imaginal disc resulted in a 30% decrease 
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in eye size with reduced cell viability. However, the co-expression of PTEN and DJ-1 
suppressed the PTEN-induced eye phenotype and rescued cell death (Kim et al., 2005; 
Kim, 2005). Application of various dietary antioxidants, such as vitamin E, melatonin, and 
vitamin C extends the lifespan of mutant flies (Kumar et al., 2017). The same result is 
observed in spirulina feeder flies along with improvement of locomotion ability. There are 
many biological functions described by which the loss of DJ-1 function protects against 
neuronal demise, but it seems most likely that the major role of DJ-1 is in response to 
oxidative stress to maintain mitochondrial integrity.  
 
The LRRK2 model 
Leucine-rich repeat kinase (LRRK2) is a large 2527 amino acid long, multidomain 
protein, which contains Ras of complex (Roc), putative serine/threonine kinase, GTPase 
domains, C-terminal of Roc (COR), kinase domain of MAPK, and leucine-rich repeat 
domain (LRR) (Lee et al., 2001). These multifunctional domains are implicated in various 
cellular modifications including alternation of enzymatic phosphorylation, cellular 
transformation, and vesicle trafficking, and stimulation of stress-activated kinase that leads 
to neuronal degeneration. The GAL4/UAS system of mediated transgenic expression of 
either wild-type human LRRK2 or LRRK2-G2019S in the photoreceptor cells caused retinal 
degeneration of Drosophila. A similar expression in neurons generated an adult-onset 
selective loss of dopaminergic neurons, locomotor dysfunction, and premature mortality 
(Liu, Z. et al., 2008). Wild-types, as well as transgenic G2019S-LRRK2 rats, have 
attenuated α-synuclein induced dopaminergic neurodegeneration and inflammation by 
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LRRK2 kinase inhibition (Daher et al., 2015). The inhibition of LRRK2 activity can have 
a disease-modifying effect (Paisán-Ruı́z et al., 2004). In double transgenic flies, various 
phenotypes of the eye and dopaminergic survival changed in a complex fashion through a 
concomitant expression of PINK1, DJ-1, or parkin (Venderova et al., 2009). LRRK2 motor 
neuron mediated proboscis extension response (PER) in Drosophila shows slower 
movements, absence of movement altogether, increased tremor, and changes in neural 
signalling (Cording et al., 2017). All this evidence suggests a genetic interaction of LRRK2 
between these PD-relevant genes. 
The role of the mitochondria in PD  
 
As the main functional organelle responsible for energy metabolism, mitochondria 
regulate several cellular processes, most significantly oxidative stress, calcium balance, 
substrate binding, and apoptosis. Disrupting mitochondrial dynamics ultimately 
contributes to neuronal cell death and neurodegenerative diseases. Complexes I to V of the 
electron transport chain within mitochondria transfer the electrons to the respiratory chain 
across the inner mitochondrial membrane by the electrochemical membrane potential 
(proton-motive force). ROS is produced, in this oxidative phosphorylation process. 
(Starkov, 2008; Murphy, 2009). An elevated level of mitochondrial ROS or defective ROS 
elimination promotes the oxidative damage of mtDNA, disturbs proteins and lipids 
signalling pathways, increases free hydroxyl radicals, and bioenergetic failure, which can 
perturb the whole process of mitochondrial ageing, fission and fusion. Analysis of 
mitochondria from the frontal cortex of PD patients demonstrated that reactive subunits of 
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complex I are oxidatively damaged, corroborating the mitochondrial effect with PD 
pathology (Winklhofer & Haass, 2010). Further explanation is required about which 
subunits are affected for better understanding. Inhibitors of complex I such as 1‐methyl‐4‐
phenyl‐1, 2, 3, 6‐tetrahydrodropyridine (MPTP), pyridaben, rotenone, trichloroethylene, 
and fenpyroximate induce dopaminergic neuronal demise in flies, humans and rodents. 
(Chaturvedi & Beal, 2008). These toxins that affect mitochondria in the flow of the electron 
transport system cause an increment in the mitochondrial membrane permeability and 
increase aberrant reactive oxygen species (ROS) (Borland et al., 2008; Bose & Beal, 2016; 
Moon & Paek, 2015). Structural changes in complex I lead to dopaminergic 
neurodegeneration, making these dopaminergic neurons more susceptible to neurotoxins 
(Perier et al., 2010). Mitochondrial DNA (mtDNA) is a double-stranded small circular 
genome which replicates independently, and contains 37 genes, which encode many 
proteins. Inhibition of midbrain dopaminergic neurons causes reduced mtDNA expression, 
respiratory chain deficiency and neuronal cell death, leading to progressive, L-dopa-
responsive impairment of motor functions in rodents (Winklhofer & Haass, 2010). Neurons 
are required to act promptly in responding to bioenergetic demand. The electrochemical 
potential of presynaptic and postsynaptic sites in neurons depends on the efficient transport 
of mitochondria. Thus, it is assumed that mitochondrial modifications can promote 
neuronal dysfunction and degeneration (Exner et al., 2012). Evidence from multiple studies 
indicates that PD-associated genes and various mutations directly or indirectly affect 
mitochondrial integrity (morphology, function, and dynamics), thereby providing a mutual 
link to pathophysiological alterations observed in sporadic and familial PD (Abou-Sleiman 
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et al., 2006). Both wild type and mutant SNCA mouse models exhibit mitochondrial 
abnormalities: degenerating mitochondria with accumulated SNCA, complex I and IV 
impairment, mtDNA damage, enhanced mitochondrial Ca2+, and oxidative modification, 
which are prevalent in mitochondria from striatum and substantia nigra (SN) of PD patients 
(Subramaniam et al., 2014). Both genes parkin and PINK1 modify mitochondrial 
biogenesis (Henchcliffe & Beal, 2008). A small portion of DJ-1 protein resides in the 
mitochondrial matrix, which inhibition in the motochondria of the fly and mouse showed 
decreased mitochondrial DNA levels, sensitivity to MPTP-induced loss of dopaminergic 
neurons, and reduced complex I activity (Lev et al., 2006). Mutation in the GTPase kinase 
domain of LRRK2 caused mitochondrial disintegration and fusion reduction alongside 
defects in intracellular protein distribution (Martin et al., 2014). HtrA serine peptidase 2 
(HTRA2) controls mitochondrial membrane permeability during programmed cell death 
and changes mitochondrial morphology via OS vulnerability (Li, B. et al., 2010). All 
(SNCA, PINK1, Parkin, DJ-1 LRRK, and HTRA2) major genes of familial PD show 
connection to mitochondrial paradigms associated with the disease including anomalies of 
the mitochondrial ETS, mutated protein deposition, age-dependent damage to mtDNA, 
impaired calcium homeostasis, altered mitochondrial morphology, and biogenesis. 
Recently added novel gene mutations, and their impact on mitochondrial functions, have 
further reinforced the relevance of mitochondrial abnormalities in PD disease 
pathogenesis. 
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The ubiquitin-proteasome system (UPS) in PD 
 
The UPS is the main pathway to carry out a highly selective degradation of short-
lived, small, intracellular misfolded as well as ubiquitinated proteins in the nuclear and 
cytoplasmic compartments (Ross et al., 2015). This system involves two consecutive steps: 
ubiquitylation-binding of ubiquitin to a substrate protein through an enzymatic cascade and 
proteasomal degradation. Multiple rounds of ubiquitylation lead to the formation of a 
polyubiquitin chain, which can provide a signal for degradation by the 26S proteasome, a 
multi-protein complex consisting of a 20S core particle and 19S regulatory particles. The 
proteasome unfolds substrates, and only the unfolded ubiquitinated polypeptide chains can 
pass through the inner channel of the proteasome barrel (Dantuma & Bott, 2014). The poly-
ubiquitin chain is synthesized by a cascade reaction consisting of three enzymes: E1 
(ubiquitin-activating enzyme) binds to a ubiquitin molecule, E2 (ubiquitin-conjugating 
enzyme) receives ubiquitin from E1, and E3 (ubiquitin-ligase enzyme) carries out proteins 
recruitment relied on substrate specificity (Hochstrasser, 1996). Targeting of the vulnerable 
proteins by ubiquitin, impaired function of the UPS, and the resultant accumulation of 
misfolded proteins have been strongly implicated in the pathogenesis of PD. This, in 
combination with increased oxidative stress, leads to the death of dopaminergic neurons, 
thereby affecting cell survival. α-synuclein, the major component of LBs in the brain is 
degraded by the 26S proteasome, and mutated α-synuclein instigates the formation of 
abnormal branches that directly interact with the 20S core of the proteasome to inhibit its 
proteolytic function (Heo & Rutter, 2011). Parkin mutations in AR-JP shows reduced 
ubiquitin-ligase enzymatic activity in the substantia nigra, which affects the UPS 
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negatively and leads to the PD neurodegeneration (Ebrahimi et al., 2012). UCH-L1 is an 
early onset AD PD susceptibility gene that is involved in regulation of substrates and 
releases ubiquitin from cellular amines. Dimerized UCH-L1 modifies α-synuclein 
ubiquitination, resulting in PD pathology (Atkin & Paulson, 2014). Another PD susceptible 
gene, the FBXO7 constitutes one of the four subunits of the ubiquitin ligase complex that 
is implicated in the UPS pathway and this gene product has been found in Lewy bodies of 
PD patients (Zhao et al., 2013). All of these observations suggest a large degree of inter 
dependable correlation between UPS and mutations in the PD genes which ultimately leads 
to the degeneration of DA neurons. 
 
The endoplasmic reticulum and Golgi body link to PD 
 
The endoplasmic reticulum (ER) is a cytoplasmic organelle that maintains protein 
homeostasis in the cell, which is a complicated stepwise process starting from synthesis to 
gradual folding, assembly, transport, and degradation of proteins. Golgi body is the 
packaging centre of the cell, which after receiving protein vesicles from the ER, proceeds 
to further modification: glycosylation, phosphorylation, proteolytic cleavage and 
trafficking to the destination (Bexiga & Simpson, 2013). ER and Golgi related dysfunctions 
hinder the anterograde and retrograde transport of proteins and lead to the accumulation of 
misfolded proteins, which activates the unfolded protein response (UPR) for cell survival 
(Wang et al., 2016). Signs of altered protein deposition in the ER lumen are visible in the 
post-mortem tissue of human and animal models of PD. Accumulation of ER-associated 
degradation substrates, and ER stress was identified as an early pathologic phenotype in 
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neurons developed from induced pluripotent stem cells of patients having α- synuclein 
mutations (Chung et al., 2013). α-Synulcein inhibits the ATF6 activating transcription 
factor and ATF6 incorporation into coat protein complex (COP)II vesicles, resulting in an 
aberrant unfolded protein response (Credle et al., 2015). It indirectly impairs ER-Golgi 
protein transport, which enhances further ER stress and apoptosis (Wang et al., 2016). 
Mutations in the E3 ubiquitin ligase parkin cause the aggregation of α-synuclein owing to 
reduced ubiquitin ligase activity, which ultimately affects both ER and Golgi body 
transport (Mercado et al., 2016). In the yeast model, the overexpression of the ER-Golgi 
trafficking genes YPT1, YKT6, BRE5, UBP3, and ERV29 suppresses α-synuclein induced 
toxicity by promoting forward ER-Golgi transport (Cooper et al., 2006). The fragmentation 
of the Golgi body is correlated with fluctuations in levels of RAB1, RAB2, RAB8 and the 
SNARE protein syntaxin-5 (STX5), but the accumulation of the pre-synaptic protein α-
synuclein could be alleviated by RAB1 and RAB8 overexpression and RAB2 and STX5 
depletion in the affected cell (Bexiga & Simpson, 2013; Rendón et al. , 2013). All of  these 
proteins are related to the early secretory pathway machinery, and they indicate that the ER 
dysfunctional trafficking, and Golgi fragmentation, occurred before α-synuclein 
aggregation, and activates the progressive formation of the inclusion bodies. 
 
The endosomal-lysosomal regulation in PD 
 
The endosomal-lysosomal system consists of interconvertible membranous 
compartments, namely early endosomes, recycling endosomes, late endosomes, and the 
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lysosome. The lysosome represents the common degradative endpoint at which the 
endosomal and autophagic pathways converge. The organization and functions of 
membrane-bound organelles dynamics (endocytic trafficking) which affect protein (α-
synuclein) accumulation (Schapira & Jenner, 2011), and degradation. Recently, rising 
evidence has suggested that the abnormalities in the physiological processes of endosomal-
lysosomal maturation, acidification, and sorting systems during the endocytic 
transport/trafficking, especially autophagy, is directly inducive to the neurological 
malfunctions, represented by PD, and Lewy body dementia (LBD) (Hu et al., 2015). 
Macroautophagy and chaperone-mediated autophagy (CMA) are the two main processes 
of autophagy lysosomal pathway (ALP) and both regulate protein degradation (wild type 
α-synuclein is degraded by the CMA) upon the accumulation of misfolded, damaged, or 
unnecessary proteins. Autophagic dysregulation causes the aggregation of abnormal 
proteins or damaged organelles, a characteristic of α-synuclein induced PD. Genes 
pertaining to recessive PD, such as PINK1 and parkin (PINK2), combinedly interact in the 
process of mitophagy, whereby defective mitochondria are selectively engulfed by 
macroautophagy (Xilouri & Stefanis, 2011). Heterozygous mutations in the lysosomal 
enzyme glucocerebrosidase (GBA1)  increase the risk of PD. LRRK2 interacts with and 
disrupts endocytosis, and late endosome-lysosome trafficking. Both the G-associated 
kinase, GAK, and RAB7L1 contribute to trans-Golgi complex formation and cause an 
impairment in endo-lysosomal trafficking and Golgi apparatus sorting (Perrett et al., 2015). 
The PD-causing D620N mutation of VPS35 in transgenic flies caused mobility 
impairments, shortened lifespans, bristles loss, eye disorganization, and increased 
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sensitivity to PD-linked environmental toxins (rotenone) (Wang et al., 2014). In 
Drosophila and mammalian cells, the D620N mutation in VPS35 resulted in α-synuclein 
accumulation in late endosomes/lysosomes, probably due to an alteration in the trafficking 
of lysosomal protease, cathepsin D, and endosomal disruptions which degrade α-synuclein 
(Follett et al., 2014; Miura et al., 2014). This mutation also reduces endosomal sorting 
WASH (Wiskott–Aldrich syndrome protein and SCAR homologue) complex recruitment 
to early endosomes, and, therefore, indicates an association with perturbing 
endosomal/lysosomal trafficking (Zavodszky et al., 2014). Like VPS35, mutations in 
DNAJC13 are related to the WASH complex inhibition to FAM21 protein binding. 
Endosomal tubules are formed by sorting nexin dimer-SNX, DNAJC13 may regulate the 
localization of the WASH complex and SNX dimer, as its suppression causes an increase 
in highly branched endosomal tubules (Freeman, 1996). Interestingly, all the genes 
mentioned above encode proteins involved in the endo-lysosomal system, and directly or 
indirectly associated with higher risk or susceptibility to PD. This strongly supports the 
notion that endosomes play a pivotal role in the disease.  
 
Gene of interest 
 
Large-scale research efforts, genome-wide association studies (GWAS), transgenic 
animal designs, next-generation sequencing (NGS), and exome sequencing 
implementation, have undeniably accelerated the identification of new phenotype-
associated genes for sporadic and monogenic PD (Kalinderi et al., 2016). Whole genome 
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expression microarrays, combined with expression quantitative trait loci (eQTL) analysis 
showed 7 of 424 genes have the presence of prominent eQTLs in various brain regions, 
including the basal ganglia, which provides insight in the PD pathway (Murthy & 
Ramachandra, 2017). Recently, through the integration of cell-based and model organism 
functional screens, it has been conferred (Jansen et al., 2017) that there are potential links 
between the 27 de novo autosomal recessive candidate genes and the well-established 
mechanisms of PD susceptibility and pathogenesis, including mitochondrial dynamics and 
α-synuclein-mediated toxicity. There is an illustration of two gene-association networks, 
the first one centered around FBXO7 and LRRK2, the second one centered around SNCA, 
PINK1, PARK2, PARK7, ATP13A2, and GBA. UHRF1BP1L is one of the five functionally 
validated genes which shows a strong interaction with PD genes of the second network 
(SNCA, PINK1, PARK2, PARK7, ATP13A2, and GBA).  
UHRF1BP1L [Ubiquitin-like PHD finger and Ring finger domain-containing 
protein 1(UHRF1) Binding Protein 1 Like] is a protein-coding gene. Alias symbols for this 
protein are KIAA 0701 and syntaxin 6-interacting protein (SHIP164). KIAA 0701 was first 
named during the prediction of the coding sequences of unidentified human genes from 
cDNA libraries of the human brain (Ishikawa et al., 1998). This gene belongs to the family 
UHRF1- binding protein-1 like and the only sequence paralogue of this gene is 
UHRF1BP1. UHRF1 is a biomarker of tumorigenesis that contains a UBL methylated H3 
histone domain, PHD domain, SRA domain, and Ring Finger with ubiquitin E3 ligase 
activity domain (Bronner et al., 2007). This protein is localized in the cytoplasm, cytosol, 
and early endosomes. This protein has two isoforms: isoform a is a 1464 amino acid 
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sequence and isoform b, a short chain of 522 amino acid sequence with a presumed 
molecular mass of 164kDa and 59kDa, respectively. The N-terminal (Chorein-N or Vps13 
domain) of UHRF1BP1L shows similarity with the N-terminus of yeast Vps13p and human 
VPS13 (human has four VPS13 genes) which is a full-length transmembrane protein with 
a role in vesicle-mediated sorting from endosome to Golgi body (Redding et al., 1996; 
Velayos et al., 2004). Chorein protein is encoded by the VPS13A gene, whose loss-of-
function mutations are responsible for the neurodegenerative disorder, Chorea 
acanthocytosis, and results in the demise of striatal neurons. This protein is visible in dense-
core vesicles of the neurite terminal in rat PC12 cells (a cell line derived from adrenal 
medulla), which contain dopamine (Hayashi et al., 2012; Tomemori et al., 2005). Taken 
together, this indicates that the Chorein-N domain might be involved in intracellular protein 
transport. UHRF1BP1L has been predicted to have a small coiled-coil region at the C-
terminus. Two domains between the N and C- terminals are inosine-5′- monophosphate 
(IMP) dehydrogenase/guanosine monophosphate (GMP) reductase (ID/GR), and 
fibronectin type III‐like fold (FNIII) (Otto et al., 2010). IMP dehydrogenase of the ID/GR 
domain has phosphate binding site and involved in the synthesis of guanosine nucleotide, 
and the deamination of GMP to produce IMP is catalyzed by GMP reductase  (Smith et al., 
2016; Zhang et al., 1999). FNIII is highly stable, encoded by 90 amino acids in human with 
an immunoglobulin (Ig)-like fold but it lacks internal disulfide bridges, which have been 
implicated in cell adhesion, elasticity, and membrane receptors (Shah et al., 2017). 
Domains attached to Ig have been found to beuseful for diagnostic and therapeutic purposes 
due to their high penetration efficiency into cells and conjugation ability to the therapeutic 
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drug (Jacobs & O'neil, 2018). Considering the above functionally significant domains of 
UHRF1BP1L, further analysis is important to uncover the molecular therapeutic aspects of 
PD. 
 
Protein trafficking role of UHRF1BP1L  
 
Membrane trafficking of proteins between organelles is mediated by vesicles that 
bud from one membranous compartment and fuse with a target compartment. The SNARE 
proteins play a crucial role in various stages of trafficking such as budding, transport, 
tethering, and fusion to target organelles (Brandhorst et al., 2006). In GST pull-down 
assays, followed by antibody regulated co-immunoprecipitation, the N-terminally placed 
Habc domain of Syntaxin 6 (SNARE protein) interacts with the predicted C -terminal 
coiled-coil domain of SHIP164 or UHRF1BP1L, which reflected the same interaction in 
yeast two-hybrid analysis. Correlated light and electron microscopy showed co-
overexpression of both Stx-6 and UHRF1BP1L in transfected cells (human embryonic 
kidney 293 cells) produce an excessive tubulation in the membranous structure of the early 
endosomes. All four (VPS51, VPS52, VPS53, and VPS54) genes of the GARP (Golgi-
associated retrograde protein) complex work together in the retrograde transport of protein 
from endosome to Golgi, which is required for the recycling of intracellular membrane 
proteins and for vacuolar protein sorting (Otto et al., 2010). Interestingly, mutations in 
VPS35, a component of the retromer complex, which is involved in endosomes to the trans-
Golgi network retrograde transport of protein, is associated with the late-onset PD (Chesi 
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et al., 2012; Vilariño-Güell et al., 2013; Zimprich et al., 2011). As well, UHRF1BP1L  
interacts with subunits (Vps52 and Rab proteins) of the Golgi-associated retrograde protein 
(GARP) and functions in membrane trafficking through the early and late endosomal 
system (Otto et al., 2010). The protein products of UHRF1BP1L have similarity in 
structure with Vps13 (Vacuolar protein sorting-associated protein 13) in the N-terminus 
and both proteins have a C-terminal coiled-coil region. The N-terminal portions of 
VPS13A and VPS13C act as lipid transporter between the endoplasmic reticulum and other 
membranous organelles. The dysfunction of lipid homeostasis due to the mutation of 
VPS13C likely shows clinical manifestations of patients with parkinsonism (Kumar et al., 
2018) . The Chorein-N domain has been noted in the UHRF1BP1L protein (Mizuno et al., 
2007), and its presence likely indicates that it has lipid transport modules similar to Vps13. 
Moreover, this gene shows involvement in protein trafficking from endosome to Golgi 
Body. This fortifies its potential role in intracellular movement and disposal of alpha-
synuclein and ubiquitin protein of PD. 
 
 
Mitochondrial dysfunction and UHRF1BP1L 
 
In both Mendelian and sporadic forms of PD, especially those that result in early 
onset of the disease, mitochondrial defects are generated by mutations in PD-related genes 
and contribute to the mitochondrial protein regulation, ETS, oxidative stress, mitophagy, 
and the fusion or fission of mitochondria (Haelterman et al., 2014; Pickrell & Youle, 2015). 
In mitochondrial mechanisms and functional control, PINK1(PARK6), parkin (PARK2) 
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and Dj-1(PARK7) have impacts that are probably related in creating oxidative stress in 
neuronal cells (Banerjee et al., 2009; Cookson, 2012). Specifically, PINK1 (mitochondrial 
kinase) and parkin (E3 ubiquitin ligase) act in combination to remove damaged 
mitochondria by mitophagy (Rüb et al., 2017). Moreover, aggregation of α-synuclein 
(SNCA), a prominent factor of Lewy bodies accumulation in PD, has induced 
mitochondrial fragmentation (Kamp et al., 2010). The interest gene UHRF1PB1L is 
significantly co-expressed with Mendelian genes including both PINK1 and SNCA in the 
subtantia nigra of the brain, and the silencing of UHRF1BP1L causes alternation of 
mitochondrial morphology, and mitochondrial numbers reduction. In addition, 
UHRF1PB1L shares proteins domains with VPS13 and VPS13C, and has been linked to 
reduced mitochondrial membrane potential, mitochondrial fractionation, increased 
respiration rates, and aggravated parkin/PINK1 system mitophagy in Parkinsonism with 
AR (Lesage et al., 2016). Neuronal disorders leukodystrophy and hypomyelination 6 are 
associated with defects in this gene. Moreover, UHRF1BP1L was mentioned as a candidate 
gene for the most common ocular disorder myopia, and another uncommon skin condition 
disseminated superficial porokeratosis (Hawthorne et al., 2013). Considering its 
relationship to other neurological diseases, and mitochondrial vulnerability to AR PD, it is 
necessary to characterize the putative AR PD gene UHRF1BP1L to understand its 
functional influence on other PD genes and pathology. 
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CG34126 gene in Drosophila melanogaster 
 
As described in this thesis, CG34126 (Fly base ID FBgn0083962) is the homologue 
gene of UHRF1BP1L in D. melanogaster, which is identified in chromosome 2L. The 
protein encoded by the gene shares its domains with the UHRF1BP1L and the N- terminal 
domain of the vacuolar protein sorting-associated protein 13 (Jansen et al., 2017). The 
CG34126 gene remains to be elaborately analyzed in Drosophila for PD, but as a novel 
candidate homologue of human gene UHRF1BP1L, it is worthwhile to analyze the 
CG34126 mediated model for elucidation of the underlying genetic and cellular basis of 
the aetiology and pathogenicity of PD. 
 
Homeostasis and Parkinson Disease 
Homeostasis is the ability of an organism to keep up a constant internal state during 
recurrent environmental changes, in such a way that its functioning remains unimpaired 
(Dobzhansky & Wallace, 1953). Modification evoked by homeostasis facing 
environmental variation within an organism almost always tend to increase cell 
proliferation, differentiation, and apoptosis which ultimately lead to the survival and 
reproduction of the animals (Eijkelenboom & Burgering, 2013). As genetically accessible 
designs and methodologies available in Drosophila melanogaster combine with recent 
outcomes, it is an ideal model organism to study the pathway of gene regulatory processes 
and the consequences of their deregulation for PD related neuronal tissue, particularly in 
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the case of metabolic and proliferative homeostasis (Beckingham et al., 2007). The 
complex molecular functions of different PD genes regulate various aspects of the cellular 
homeostasis, such as Parkin's E3 ubiquitin ligase activities on outer mitochondrial 
membrane stimulate autophagy, PINK1 activating parkin is responsible for mitochondrial 
dysregulation and neuronal survival or apoptosis, and DJ-1 acts as an oxidative stress 
sensor (Drapalo & Jozwiak, 2017; Pickrell & Youle, 2015). Dopaminergic neurons have a 
vital influence on circadian incapacitation which ultimately leads to circadian system 
alternation and functional variation in PD (Videnovic & Golombek, 2017). The purpose of 
this novel UHRF1BP1L gene study is to characterize it and determine how its functional 
cellular adjustments, and correlation with established genes contribute in developing 
homeostasis occurrences in humans with PD through the Drosophila model. 
 
Goals and Objectives 
To understand the role of human gene UHRF1BP1L in Parkinson Disease, I will 
investigate the consequences of altering expression of the homologue in Drosophila 
melanogaster to make novel model of Parkinson Disease. In brief, the following goals and 
objectives are the central focus of this academic work:  
1. Explore the conservation in Drosophila of the recently identified PD gene, UHRF1PB1L 
through bioinformatic analysis. 
2. Evaluate the effects, if any, upon expression of CG34126 in the developing Drosophila 
melanogaster eye. 
32 
 
3. Determine if inhibition and overexpression of CG34126 may influence longevity and/or 
climbing ability over time. 
4. Determine if alteration of CG34126 expression may influence longevity and/or climbing 
ability over time in the previously established park loss-of-function Drosophila 
melanogaster  model of PD. 
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Methods and Materials 
 
Bioinformatic assessment 
A number of bioinformatic tools were applied to understand the potential biological 
function of the Drosophila melanogaster homologue of the human gene UHRF1BP1L. The 
nucleotide sequence of the human PD candidate gene UHRF1BP1L (NC_000012.12), the 
homologueous gene of Drosophila melanogaster CG34126 (NT_033779.5) and other 
species genes were sourced from National Center for Biotechnology Information (NCBI) 
website (https://www.ncbi.nlm.nih.gov) and fly Base website (https://flybase.org/). To 
identify the Drosophila melanogaster homologue (NT_033779.5) of human UHRF1BP1L, 
a translated nucleotide data base using protein query search (tBLASTn) was performed 
using the Basic Local Alignment Search Tool BLAST (www.ncbi.blast.com).  For multiple 
sequence alignment, Cluster Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/) and for 
two sequences, Pairwise Sequence Alignment (https://www.ebi.ac.uk/Tools/psa/), were 
applied to demonstrate identity (fully conserved residues) and similiarity (likelihood for 
sequence homology) of protein sequences. Conserved domains in UHRF1BP1L protein 
sequences of both vertebrate and invertebrate species were identified using the Conserved 
Domain Database (CDD) (Derbyshire et al., 2015; Geer et al., 2002) tools of NCBI 
(https://www.ncbi.nlm.nih.gov/cdd) and domain identification software Pfam (Mizuno et 
al. 2007) (https://pfam.xfam.org/).  
Drosophila stocks and derivative lines 
The stocks used to direct the overexpression of CG34126, y[1] w[67c23]; 
P{w[+mC] y[+mDint2] =EPgy2} EY11029 (designated as UAS-CG34126EY) were 
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obtained from the Bloomington Drosophila Stock Center, Indiana University, 
Bloomington, USA (stock number BDSC:20245). The stocks utilized to direct the RNA-
interference of CG34126, P{KK108307} VIE-260B (designated as UAS-CG34126-
RNAiKK) and w[1118]; P{GD11162} v26336 (designated as UAS-CG34126-RNAiGD) were 
obtained from the Vienna Drosophila Resource Center, Austria (stock numbers 
VDRC107307 and VDRC26336, respectively). Detailed information about these stocks are 
available from http://www.flybase.org. With regards to the Gal4 bearing transgenic lines, 
the dopa decarboxylase (Ddc)-Gal4 fly line (BDSC7010)  (Li et al., 2000) was provided 
by Dr. J. Hirsh (University of Virginia). The tyrosine hydroxylase (TH)-Gal4, 
(BDSC:8848) (Friggi et al., 2003), glass multiple reporter (GMR)-Gal4 (BDSC:1104) 
(Freeman, 1996), D42-Gal4 (BDSC:8816) (Yeh et al., 1995), and control line UAS-lacZ 
(BDSC:1776) (Brand et al., 1994) were obtained from the Bloomington Drosophila Stock 
Centre at Indiana University. Derivative line Ddc-Gal4/CyO; UAS-park-RNAi/TM3 was 
generated and tested in the Dr. Brian E Staveley lab using standard homologous 
recombination methods. See Table 2 for a full list of all genotypes used. 
Male progeny was selected to observe CG34126 gene effect on flies to keep up 
consistency throughout the whole experiment. Moreover, reproductive stress is significant 
in females as far as ageing is concern and isolating virgin females could make this 
experiment much more time-consuming. However, the evaluation of females can certainly 
be done in future. 
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Table 2: Genotypes of all stocks used to characterize CG34126 in this study  
Genotypes Abbreviation Expression Balancer References 
Control Line 
w; UAS-lacZ4-1-2 
 
UAS-lacZ   (Brand et 
al., 1994) 
Gal4 directed expression  
Lines 
  
 
  
w;GMR-Gal412 GMR-Gal4 Eye  (Freeman, 
1996) 
w[*]; 
P{w[+mW.hs]=GawB}D42 
D42-Gal4 Motor 
neurons 
 (Yeh et al.,  
1995) 
w1118; P{Ddc-Gal4.L}4.3D Ddc-Gal4 Dopaminergic 
and other 
Neurons 
 (Li et al., 
2000) 
w*; P{ple-Gal4.F}3 TH-Gal4 Dopaminergic 
Neurons 
 (Friggi‐
Grelin et 
al., 2003) 
Experimental Lines     
B20245: y [1] w[67c23]; 
P{w[+mC] y[+mDint2] 
=EPgy2} EY11029 
 
UAS-
CG34126EY 
  (Bellen et 
al., 2011) 
w1118; P{GD11162}v26336 
 
UAS-
CG34126-
RNAiGD 
  (Jansen et 
al., 2017) 
P{KK108307}VIE-260B UAS-
CG34126-
RNAiKK 
  (Jansen et 
al., 2017) 
Derivative Lines 
w; ddc-Gal4/CyO; UAS-
park-RNAi/ 
TM3 
 
 
Ddc-Gal4; 
UAS-park-
RNAi 
 
 
Dopaminergic 
Neurons 
CyO; 
Curly 
wings 
(Curly) 
TM3; 
Tubby 
Body 
Staveley 
research 
group 
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Media and culture 
Stocks of Drosophila melanogaster were reared in a standard cornmeal, yeast, 
molasses and agar medium. The medium used by the research group of Dr. Brian Staveley 
is composed of 65 g/L cornmeal, 15 g/L nutritional yeast, and 5.5 g/L agar in distilled water 
which is sterilized by autoclave. During cooling, 50 ml/L fancy grade molasses was added 
and then, to counter spoilage, 5 ml of 0.1 g/mL methyl-4-hydroxybenzoate paraben in (95% 
ethanol) and 2.5 mL of propionic acid were added prior to being aliquoted. Prepared 
medium was poured into plastic vials, refrigerated at 4 °C to 6 °C for solidification up to 3 
weeks and equilibrated to room temperature before use. Stocks were raised and moved into 
new media every 2 or 3 days to avoid crowdedness and increase breeding rate (Merzetti et 
al., 2016). Male and female flies were crossed to observe phenotypic expression of the 
target gene and crosses and experiments were kept at 25 °C. 
 
Biometric analysis of Drosophila eye 
The compound eye of Drosophila was taken to examine phenotypic characters such 
as eye shape, ommatidia, and bristle number. Male flies of each individual cross were 
collected in groups of up to 20 after eclosion and matured for 2 or 3 days on standard media, 
followed by freezing at -80 °C. Selected flies were mounted on scanning electron 
microscope studs placing left eyes upwards, desiccated overnight, and eye images were 
taken using the FEL Mineral Liberation Analyzer 650F, located at Bruneau centre for 
innovation and research, and magnification ranges from 550X - 650X. At least 10 
micrographs of each cross were analyzed by the National Institute of Health (NIH) ImageJ 
software (https://imagej.nih.gov/ij/download.html) and GraphPad Prism version 8.0.0 was 
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used for performing biometric assay (Schneider et al., 2012). Comparison of the measured 
parameters was done by t-test (p<0.05). 
 
Lifespan analysis 
Vials containing flies were kept at temperature 25 °C for results comparison and up 
to two hundred adult male flies of each genotype were collected and from them twenty flies 
were stored in per vial on fresh media. Every 48 hours, flies were checked for viability, 
media were changed twice in a week or whenever deceased flies were found. Analysis of 
survival data was carried out using GraphPad Prism version 8.0.0 and different curves are 
compared using the log-rank (Mental-Cox) test (M’Angale & Staveley, 2016b). 
Significance was determined at 95%, at a P value less than or equal to 0.05 with Bonferroni 
correction. 
 
Climbing analysis 
Locomotor ability represents the motor control of flies throughout their lifespan. 
The climbing equipment was a glass tube which is 30 cm in length and 1.5 cm in diameter. 
It was labelled with a series of five lines, each 2 cm apart (scored 1-5), with a buffer region 
at the top of the apparatus. Fifty male progenies of each genotype were collected after 
eclosion and separated into a group of ten flies. Seven days after collection and every week 
thereafter, flies were assessed for 10 seconds climbing to 10 times per vial of 10 flies. Flies 
were tranferred from vial to climbing tube carefully without using CO2. Results were 
calculated by the following formula: 
Climbing index = ∑ (nm) / N  
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where n=number of flies at a given level, m=the score for that level (1-5) and N=total 
number of flies climbed for that trial. After examining the climbing ability, a regression 
curve was applied with a 95 % confidence interval to analyze the graphs of 5-climbing 
index within a given time for each genotype. The slope for each graph represents the rate 
of decline in climbing ability and the Y-intercept represents the initial climbing ability; 
both slope and Y-intercept were not constant across all groups, so it was needed to 
incorporate parameters into statistical analysis to determine the variation in climbing 
ability. (Merzetti, E. M. & Staveley, 2016; Todd & Staveley, 2004). A comparison of fits 
demonstrated whether or not curves varied between groups. 
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Results 
Bioinformatics analysis 
Identification of the Drosophila melanogaster homologue of UHRF1BP1L  
 
The amino acid sequence of the Homo sapiens UHRF1BP1L protein (NP_055869.1) of 
1464 residues was obtained from the NCBI website. A tBLASTn search of the Drosophila 
melanogaster genome was conducted and gene CG34126 (NP_001260065.1) was 
identified as the protein sequence most similar to Homo sapiens UHRF1BP1L, with 1475 
amino acids. These two sequences were aligned using, Pairwise Sequence Alignment and 
Clustal Omega multiple sequence alignment to identify regions and percentage of 
similarity. The proteins share 405 identical, 397 highly conserved, and 99 less conserved 
amino acids; the overall identity and similarity between the human and Drosophila 
melanogaster proteins were 26.5% and 41.5%, respectively (Figure 2). UHRF1BP1 is the 
paralogue gene of human UHRF1BP1L. The human protein sequence of UHRF1BP1 
protein of 1440 amino acids was obtained from NCBI (NP_060224.3) and it was aligned 
with the Drosophila melanogaster CG34126 (NP_001260065.1) amino acids sequence. 
The proteins share 309 identical, 294 highly conserved, and 192 less conserved amino 
acids; the overall identity and similarity between the proteins were 26.7% and 42.5%, 
respectively.  The conserved Domain Database (CDD) of NCBI and Pfam were used for 
the identification of domains Chorein-N, VPS13, ID/GR, FNIII, and coiled-coil (CC) 
(Figure 2 and 4). Pairwise Sequence Alignment of UHRF1BP1L domains with CG34126 
showed Chorein-N (identity-57.2%; similarity-72.2%), VPS13 (identity-37.3%; similarity-
55.4%), FNIII (identity-21.2%; similarity- 46.2%), ID/GR (identity-13.3% and similarity-
20.1%), and CC (identity-6.8% and similarity-13.6%) (Figure 3). 
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Figure 2. Alignment of protein encoded by Drosophila melanogaster CG34126 with 
the two human UHRF1BP1 and UHRF1BP1L protein. 
Clustal Omega multiple sequence alignment of human UHRF1-binding protein1 
(UHRF1BP1) (Homo1 is Homo sapiens NP_060224.3) and human UHRF1-binding 
protein1-like protein (UHRF1BP1L) (Homo1like is Homo sapiens NP_055869.1) with the 
Drosophila melanogaster CG34126 protein (Drosophila is Drosophila melanogaster 
NP_001260065.1) showing the highlighted domain Chorein-N (black), VPS13(yellow), 
ID/GR (light blue), FNIII (oranke), CC (light pink), and NLS (purple). The domains were 
identified using CD-search tool of NCBI Conserved Domain Database Search (CDD) and 
Pfam. "*" (Asterisk) indicates the residues that are identical, ":" (Colon) indicates the 
strongly similar, "." (Period) indicates the weakly similar. Colors show the chemical nature 
of amino acids. Red is small hydrophobic (including aromatic Y), Blue is acidic, Magenta 
is basic, and Green is basic with hydroxyl or sulfhydryl or amine groups. Grey is unusual 
amino acids.  
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Figure 3. Pairwise Sequence Alignment of UHRF1BP1L and CG34126 domains. 
Alignment of UHRF1BP1L domains with CG34126 showed Chorein-N (identity-57.2%; 
similarity-72.2%), VPS13 (identity-37.3%; similarity-55.4%), FNIII (identity-21.2%; 
similarity- 46.2%), ID/GR (identity-13.3% and similarity-20.1%), and CC (identity-6.8% 
and similarity-13.6%). 
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Figure 4. (A) Drosophila melanogaster CG34126 protein (1475 amino acid residues) 
and (B) Homo Sapiens UHRF1BP1L protein (1464 amino acid residues) with 
conserved domains. 
Highlighted domains are Chorein-N (black), VPS13 (Yellow), ID/GR (light blue), FNIII 
(oranke), and CC (pink) 
UHRF1BP1L and CG34126 are conserved between vertebrates and 
invertebrates 
 A BLASTn search of NCBI identified potentially homologous versions of 
vertebrate and invertebrate UHRF1BP1L-related-protein, including Homo sapiens 
UHRF1-binding protein 1-like protein (NP_055869.1), Zebrafish uhrf1bp1l Danio rerio 
(NP_001093475.1), house mouse Mus musculus (NP_083442.2), frog uhrf1bp1l Xenopus 
laevis (NP_001084948.1), honey bee (Apis mellifera (XP_006559910.2), silk moth 
(Bombys mori XP_012551608.1 and Dmel/CG34126 Drosophila melanogaster 
(NP_001260065.1); were aligned by Clustal Omega multiple sequence alignment to 
identify amino acids similarity. The multiple sequence alignment of vertebrate and 
invertebrate UHRF1BP1L proteins was performed using the CD-search tool of NCBI 
Conserved Domain Database Search (CDD) and Pfam for identification of conserved and 
functional domains; the result showed that Chorein-N and VPS13L domains were all 
highly conserved among the different proteins (Figure 5).   
Chorein-N VPS13 ID/GR like FNIII like CC like 
            
            
CC FNIII ID/GR Chorein-N VPS13 
N-terminal 
C-terminal 
N-terminal C-terminal 
3 96 137 364 740 1069 1266 
 
 
1363 1423 1450 
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Figure 5. Alignment of human UHRF1BP1L protein with similar protein from 
selected vertebrates and invertebrates. 
Clustal Omega multiple sequence alignment of Homo sapiens UHRF1-binding protein 1-
like protein (Homo is Homo sapiens NP_055869.1) with the Zebrafish uhrf1bp1l (Danio 
is Danio rerio NP_001093475.1), house mouse Uhfr1bp1l (Mus is Mus musculus 
NP_083442.2), frog uhrf1bp1l (Xenopus is Xenopus laevis NP_001084948.1), the honey 
bee (Apis is Apis mellifera XP_006559910.2), silk moth (Bombys is Bombys mori 
XP_012551608.1), and Dmel/CG34126 (Drosophila is Drosophila melanogaster 
NP_001260065.1). The domains were identified using the CD-search tool of NCBI 
Conserved Domain Database Search (CDD) and Pfam.  "*" (Asterisk) indicates the 
residues that are identical, ":" (Colon) indicates the strongly similar, "." (Period) indicates 
the weakly similar. Colors show the chemical nature of amino acids. Red is small 
hydrophobic (including aromatic Y), Blue is acidic, Magenta is basic, and Green is basic 
with hydroxyl or sulfhydryl or amine groups. Grey is unusual amino acids. Black and 
yellow represent the shared domains of proteins.  The proteins of the seven species share 
150 identical, 221 highly conserved, and 77 less conserved amino acids. 
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Analysis of the consequences of altered expression in the developing eye 
  
Effects of overexpression and RNA interference of CG34126 in eye phenotypes 
 
The compound eye development of D. melanogaster compound eye is very precise 
and regular. The development and organization of each ommatidium and its array is tightly 
controlled (Thomas & Wassarman, 1999). Each eye is composed of approximately 700 to 
800 ommatidia under normal conditions. The eye is a photoreceptor organ, controlled by 
neurons. If any neurodegeneration occurs, it may result changes to ommatidia area, 
ommatidia and bristle numbers or appearance of rough eye. To observe any type of 
phenotypic changes in eyes controlled by neurons, we did biometric analysis to determine 
whether overexpression or RNA-interference of CG34126 has any effect on the 
development of specialized neurons in the visual unit. The eye specific transgenic line 
GMR-Gal4 was used to express CG34126 transgenes. A summary of ommatidia and bristle 
number is demonstrated in Table 3. Analysis of the scanning electron micrographs is 
showed in the Figure 6. 
Scanning electron micrographs of eyes through overexpression or inhibition 
indicated that there were no significance changes in the ommatidium number (Figure 7A) 
and the bristle numbers compare to control (Figure 7B), when these transgenes were 
expressed in the eyes by GMR-GAL4 (Table 3A and 3B). 
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Figure 6. Eye of critical class of Drosophila melanogaster with altered CG34126 
expression visualised by scanning electron microscopy.  
A) GMR-Gal4/UAS-lacZ; B) GMR-Gal4/ UAS-CG34126EY; C) GMR-Gal4/ UAS-
CG34126-RNAiGD; D) GMR-Gal4/ UAS-CG34126-RNAiKK. There is no significant 
differences in the number of ommatidia or inter-ommatidial bristles. Images were captured 
with a FEI MLA 650 Scanning Electron Microscope. 
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Figure 7. Biometric analysis of Drosophila melanogaster eye with altered CG34126 
expression. (A) Ommatidium number and (B) bristle number. 
There was no significance change in the ommatidia numbers and bristle when 
overexpression and knockdown of CG34126 genes were analyzed in the eye. All counts 
compared to a UAS-lacZ control, comparisons were measured using a one-way ANOVA 
and significance was tested by unpaired t-test (P<0.05 and 95%CI), number of eyes=10.  
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Table 3: Biometric analysis of the directed overexpression and RNA interference of 
CG34126 in the developing Drosophila eye. 
A. Ommatidia number 
Genotypes Mean 
number 
Ommatidium 
Mean 
difference 
± SEM 
 
Significance (P-
value compare 
to control) 
95% 
confidence 
interval 
GMR-Gal4; 
UAS-lacZ 
662.3 
 
   
GMR-Gal4; 
UAS-
CG34126EY 
 
659.2 
 
 
-3.100 ± 14.45 
 
0.8326 
No 
-33.46 to 27.26 
 
GMR-Gal4; 
UAS-CG34126-
RNAiGD 
 
650.0 -12.30 ± 9.408 
 
0.2075 
No 
-32.07 to 7.466 
 
GMR-
Gal4;UAS-
CG34126-
RNAiKK 
 
659.9 
 
-2.400 ± 10.59 
 
0.8232 
No 
-24.64 to 19.84 
 
 
B. Inter-ommatidia bristle number 
Genotypes Mean 
number 
Bristle 
Mean 
difference 
± SEM  
Significance (P-
value compare 
to control) 
95% confidence 
interval 
GMR-Gal4; UAS-
lacZ 
601.8 
 
   
GMR-Gal4; UAS-
CG34126EY 
 
580.1 
 
-21.70 ± 15.99 
 
0.1915 
No 
 
-55.29 to 11.89 
 
 
GMR-Gal4; UAS-
CG34126-RNAiGD 
 
583.2 
 
-18.60 ± 8.886 
 
0.0508 
No 
-37.27 to 0.06973 
 
GMR-Gal4;UAS-
CG34126-RNAiKK 
 
581.9 
 
-19.90 ± 9.500 
 
0.0506 
No 
-39.86 to 0.05876 
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Overexpression and inhibition of CG34126 gene in selected neurons 
 
A prominent feature of PD is the age-dependent degeneration of dopaminergic 
neurons. The selective demise and degeneration of these dopaminergic neurons lead us to 
investigate the effects of UHRF1BP1L on these neurons. To observe the phenotypic 
(ageing and climbing) effects of CG34126 transgenes on the DA and motor neuronal loss 
of Drosophila, different control and experimental lines both were overexpressed and 
silenced via RNA interference and directed by D42-Gal4, Ddc-Gal4, and TH-Gal4 
transgenes. The ageing analysis was carried out simultaneously with the climbing assay in 
order to determine the changes in the climbing ability as a result of premature senescence.  
 
Lifespan analysis 
 
The effects of loss-of-function and gain-of-function of CG34126 
 
To investigate the effects of gain-of-function and loss-of-function of CG34126 on 
longevity, the Gal4-expressing lines D42-Gal4, Ddc-Gal4 and TH-Gal4 were used to cross 
with control UAS-lacZ and experimental lines to direct the expression of the CG34126 
transgenes in the fly DA neurons. There was a significance difference in the lifespan of 
flies when CG34126 transgenes were overexpressed and inhibited in the motor neurons 
directed by D42-Gal4 and survival curves were demonstrated in Figure 8. The inhibition 
of UAS-CG34126-RNAiGD demonstrated a significant reduction in longevity of flies 
compared to lacZ control. The median lifespan for UAS-CG34126-RNAiGD line was 56 
days verses 64 days for the control (Table 4). The log-rank test showed that the longevity 
curve was significantly different (p<0.0001) from the control curve. Overexpression of 
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UAS-CG34126EY and another inhibition line UAS-CG34126-RNAiKK showed no significant 
decrease in mean lifespan compared to lacZ control, and median lifespans of both lines 
were 62 days. Both the loss-of-function of UAS-CG34126-RNAiGD and overexpression of 
UAS-CG34126EY significantly reduced survival ability of flies (Figure 9) compared to lacZ 
control using Ddc-Gal4, which had mean lifespans of 62, 62 and 70 days (Table 5), 
respectively. The mean life span of UAS-CG34126-RNAiKK transgenic flies was 72 days, 
which was not statistically significant verses to the control. Statistical analysis of longevity 
is summarized in Table 5. Like the D42-Gal4 and Ddc-Gal4 directed expression lines, 
inhibition of UAS-CG34126-RNAiGD in DA neurons by TH-Gal4 resulted in a prominent 
reduction of longevity compared to control (Figure 10) and statistical analysis from table 
6 showed median lifespan of this line was 70 days verses 76 days for the lacZ-expressing 
control. The log-rank test showed that the longevity curve was significantly different 
(p<0.0001) from the control curve. The overexpression of UAS-CG34126EY and inhibition 
line UAS-CG34126-RNAiKK had no significant decrease in mean lifespan compared to the 
lacZ control, and median lifespan of these overexpressed and inhibited lines were 74 and 
78 days (Table 6). It was evident that loss-of-function of CG34126 in fly dopaminergic 
neurons leads to a reduction in lifespan, which is characteristic of PD-like phenotype, 
whereas overexpression except Ddc-Gal4 directed flies are aligned to normal flies. 
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Figure 8. Longevity curves of flies with altered expression of CG34126 in the motor 
neurons. 
Inhibition of UAS-CG34126-RNAiGD directed by D42-Gal4 results in decreased survival 
compared to the control UAS-lacZ. UAS-CG34126-RNAiKK expression in dopaminergic 
neurons causes no significant decrease in mean lifespan compared to lacZ control, while 
overexpression of UAS-CG34126EY results almost same as lacZ control. Longevity was 
shown as a percent survival (P<0.05 as determined by the Mantel-Cox Log Rank test). 
Significance was determined at 95%, at a P value less than or equal to 0.05 with Bonferroni 
correction. Error bar represents standard error and see Table 4 for n values. 
Table 4: Comparison of survival of flies with altered expression of CG34126 by D42-
GAL4 by (Mantel-Cox) Log-rank test. 
Genotypes Number of 
flies 
Mean survival 
  Days 
P-value 
(Bonferroni 
correction) 
compare to 
control 
Significance 
D42-Gal4; UAS-
lacZ 
309 64 N/A N/A 
D42-Gal4; UAS-
CG34126EY 
303 62 <0.2816 No 
D42-Gal4; UAS-
CG34126-
RNAiGD 
300 56 <0.0001 Yes 
D42-Gal4;UAS-
CG34126-
RNAiKK 
296 62 <0.2224 No 
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Figure 9. Longevity curves of flies with altered expression of CG34126 in the 
dopaminergic neurons. 
Knockdown of UAS-CG34126-RNAiGD and overexpression of UAS-CG34126EY in the DA 
neurons directed by Ddc-Gal4 resulted in decreased survival compared to the control UAS-
lacZ. UAS-CG34126-RNAiKK expression in dopaminergic neurons caused no significant 
decrease in mean lifespan compared to lacZ control. Longevity was shown as a percent 
survival (P<0.05 as determined by the Mantel-Cox Log Rank test). Significance was 
determined at 95%, at a P value less than or equal to 0.05 with Bonferroni correction. Error 
bar represents standard error and see Table 5 for n values. 
Table 5: Comparison of survival of flies with altered expression of CG34126 by Ddc-
GAL4 by (Mantel-Cox) Log-rank test. 
Genotypes Number 
of flies 
Mean 
survival 
  Days 
P-value 
(Bonferroni 
correction) 
compare to 
control 
Significance 
Ddc-Gal4; UAS-lacZ 291 70 N/A N/A 
Ddc-Gal4; UAS-
CG34126EY 
302 62 <0.0001 yes 
Ddc-Gal4; UAS-
CG34126-RNAiGD 
308 62 <0.0001 Yes 
Ddc-Gal4;UAS-
CG34126-RNAiKK 
303 72 <0.0667 No 
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Figure 10. Longevity curves of flies with altered expression of CG34126 in the motor 
neurons. 
Overexpression of UAS-CG34126EY and Inhibition of UAS-CG34126-RNAiKK in the 
dopaminergic neurons directed by TH-Gal4 had no prominent effect on lifespan compared 
to the control UAS-lacZ but knockdown of UAS-CG34126-RNAiGD in dopaminergic 
neurons causes significant decrease in mean lifespan compared to lacZ control. Longevity 
was shown as a percent survival (P<0.05 as determined by the Mantel-Cox Log Rank test). 
Significance was determined at 95%, at a P value less than or equal to 0.05 with Bonferroni 
correction. Error bar represents standard error and see table 6 for n values. 
Table 6: Comparison of survival of flies with altered expression of CG34126 by TH-
GAL4 by (Mantel-Cox) Log-rank test. 
Genotypes Number of flies Mean 
survival 
  Days 
P-value 
(Bonferroni 
correction) 
compare to 
control 
Significance 
TH-Gal4; UAS-lacZ 
 
303 76 N/A N/A 
TH-Gal4; UAS-
CG34126EY 
299 74 <0.3502 No 
TH-Gal4; UAS-
CG34126-RNAiGD 
301 70 <0.0001 Yes 
TH-Gal4;UAS-
CG34126-RNAiKK 
306 78 <0.1922 No 
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Climbing analysis of the control and experimental lines 
The effects of loss-of-function and gain-of-function of CG34126 
The climbing analysis was carried out to investigate whether the interference of 
expression and overexpression of CG34126 has any effect on dopaminergic neurons, which 
would have an effect on fly mobility. The effects of gain-of-function and loss-of-function 
of CG34126 on climbing ability were investigated using the lines D42-Gal4, Ddc-Gal4 
and TH-Gal4 in order to express the transgenes in the fly dopaminergic, motor and other 
neurons. Inhibition of CG34126 utilizing all three Gal4 directed lines significantly 
decreased climbing ability compared to the lacZ-expressing control (Figure 11, 12, and 13, 
Table 7, 8, and 9). The 95% confidence interval for D42-Gal4/ UAS-CG34126-RNAiGD and 
D42-Gal4/ UAS-CG34126-RNAiKK were 0.04441 to 0.06170 and 0.02883 to 0.03828 
(Table 7), for Ddc-Gal4/ UAS-CG34126-RNAiGD and Ddc-Gal4/ UAS-CG34126-RNAiKK 
were 0.008707 to 0.03684 and 0.03023 to 0.04347 (Table 8), and for TH-Gal4/ UAS-
CG34126-RNAiGD and  TH-Gal4/ UAS-CG34126-RNAiKK were 0.02651 to 0.04898 and 
0.03056 to 0.04281 (Table 9). These climbing curves are significantly different from the 
control curves with 95% confidence intervals at 0.04337 to 0.06121 for D42-Gal4, 0.06331 
to 0.09724 for Ddc-Gal4, and 0.04581 to 0.06941 for TH-Gal4. Overexpression of 
CG34126 using D42-Gal4 (Figure 11) and TH-Gal4 (Figure 13) did not show significant 
decline or increase in climbing ability compared to the lacZ-expressing control except   
Ddc-Gal4/ UAS-CG34126EY  with 95% confidence interval of 0.03723 to 0.05627, which 
indicates less climbing ability compare to standard line (Table 8). The 95% confidence 
interval for D42-Gal4/ UAS-CG34126EY  was 0.03144 to 0.04416, and TH-Gal4/ UAS-
CG34126EY  was 0.03368 to 0.06038.  
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Figure 11. Climbing ability over time of flies with altered expression of CG34126 in 
motor neurons. 
Both inhibition of UAS-CG34126-RNAiGD and UAS-CG34126-RNAiKK in the motor 
neurons directed by D42-Gal4 results in reduced climbing ability as determined by non-
linear fitting of the climbing curves and comparing at 95% confidence intervals. 
Overexpression UAS-CG34126EY had no significant effect on locomotor ability compared 
to the control. Error bar represents standard error and n=50. 
Table 7: Comparison of climbing ability of flies with altered expression of CG34126 
by D42-GAL4. 
Genotypes Standard 
error 
95%CI R 
square 
P value Significance 
D42-Gal4; 
UAS-lacZ 
0.004986 
 
0.04337 to 
0.06121 
 
0.8290 
 
  
D42-Gal4; 
UAS-
CG34126EY 
0.003430 
 
0.03144 to 
0.04416 
 
0.8209 
 
<0.0656 No 
D42-Gal4; 
UAS-CG34126-
RNAiGD 
 
0.004775 
 
0.04441 to 
0.06170 
 
0.8614 
 
<0.0001 Yes 
D42-Gal4;UAS-
CG34126-
RNAiKK 
 
0.002494 
 
0.02883 to 
0.03828 
 
0.8677 
 
<0.0001 Yes 
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Figure 12. Climbing ability over time of flies with altered expression of CG34126 in 
motor neurons. 
Knockdown of UAS-CG34126-RNAiKK and UAS-CG34126-RNAiGD  , and overexpression 
of UAS-CG34126EY directed by Ddc-Gal4 decreased climbing ability over time compared 
to the control lacZ when expressed by dopaminergic neurons specific transgene as obtained 
by non-linear fitting of the climbing curves. Error bar represents standard error and n=50. 
Table 8: Comparison of climbing ability of flies with altered expression of CG34126 
by Ddc-GAL4. 
Genotypes Standard error 95%CI R square P value Significance 
Ddc-Gal4; UAS-
lacZ 
0.007273 
 
0.06331 to 
0.09724 
 
0.8449 
 
  
Ddc-Gal4; UAS-
CG34126EY 
0.004507 
 
 
0.03723 to 
0.05627 
 
0.8044 
 
<0.0001 Yes 
Ddc-Gal4; UAS-
CG34126-RNAiGD 
0.006747 
 
0.008707 to 
0.03684 
 
0.2776 
 
<0.0001 Yes 
Ddc-Gal4;UAS-
CG34126-RNAiKK 
 
0.003491 
 
0.03023 to 
0.04347 
 
0.8073 
 
<0.0001 Yes 
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Figure 13. Climbing ability over time of flies with altered expression of CG34126 in 
motor neurons. 
Overexpress of UAS-CG34126EY had no significant effect on locomotor ability compared 
to the control when expressed by TH-GAL4 transgene, but inhibition of both UAS-
CG34126-RNAiKK and UAS-CG34126-RNAiGD caused decreased climbing ability 
compared to control lacZ as obtained by non-linear fitting of the climbing curves and 
analyzing at 95% confidence intervals. Error bar represents standard error and n=50. 
Table 9: Comparison of climbing ability of flies with altered expression of CG34126 
by TH-GAL4. 
Genotypes Standard 
error 
95%confidence 
interval 
R2 p-value Significance 
TH-Gal4; UAS-
lacZ 
0.006012 
 
0.04581 to 
0.06941 
 
0.8077 
 
  
TH-Gal4; UAS-
CG34126EY 
0.007513 
 
0.03368 to 
0.06038 
 
0.6456 
 
0.3596 No 
TH-Gal4; UAS-
CG34126-
RNAiGD 
0.08034 
 
0.02651 to 
0.04898 
 
0.6225 0.0358 Yes 
TH-Gal4;UAS-
CG34126-
RNAiKK 
 
0.003243 
 
0.03056 to 
0.04281 
 
0.8238 
 
0.0008 Yes 
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Expression of CG34126 in the park interference model of PD 
The co-expression of the experimental lines with park (Ddc-GAL4/CyO; UAS-
park-RNAi/TM3) was carried out to determine the effects of overexpression and inhibition 
of the UHRF1BP1L homologue CG34126 in the dopaminergic neurons. Both ageing and 
climbing ability were analyzed and compared to results obtained in park- RNA interference 
expressing control flies. 
Longevity analysis of the control and experimental lines in the park model    
The co-expression of CG34126 transgenes with parkin demonstrated various 
survival curves. Inhibition of UAS-CG34126-RNAiGD and UAS-CG34126-RNAiKK had a 
reduction in survival ability when they crossed with Ddc-Gal4;UAS-park-RNAi ( Figure 
14 and Table 10). Median survival was 40 days for UAS-CG34126-RNAiGD, which 
prominently varied compare to the 46 days of control lacZ when both lines were directed 
by dopaminergic transgene Ddc-Gal4;Uas-park-RNAi. On the other hand, there was no 
statistical significance between the lifespan capability of UAS-CG34126-RNAiKK and UAS-
lacZ control when they crossed with Ddc-Gal4;UAS-park-RNAi.  
Overexpression of CG34126 in dopaminergic neurons rescues UAS-park-RNAi 
mediated loss of longevity 
Strikingly, the co-expression of UAS-CG34126EY with park-RNAi showed an 
improvement in the lifespan of flies when expressed in the dopaminergic neurons (Figure 
14 and Table 10). Median lifespan was 54 days for the flies generated from the crossing of 
UAS-CG34126EY and Ddc-Gal4;UAS-park-RNAi, which was significantly higher than the 
median lifespan (46 days) of the control lacZ and Ddc-Gal4;UAS-park-RNAi mediated 
flies. 
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Figure 14. Longevity of flies with inhibition of park along with altered expression of 
CG34126 in Ddc-GAL4 expressing neurons. 
 Inhibition of UAS-CG34126-RNAiGD had  reduced survival rate compared to the control 
UAS-lacZ and inhibition of UAS-CG34126-RNAiKK did not significantly differ with the 
control. The longevity of flies increased when UAS-CG34126EY co-expressed with Ddc-
Gal4;UAS-park-RNAi. Genotype Longevity was shown as a percent survival (P<0.05 as 
determined by the Mantel-Cox Log-Rank test). Significance was determined at 95%, at a 
P value less than or equal to 0.05 with Bonferroni correction. Error bar represents standard 
error and see table 10 for n values. 
Table 10: Comparison of survival of flies with inhibition of park along with altered 
expression of CG34126 in Ddc-GAL4 expressing neurons by (Mental-Cox) Log-rank 
test. 
Genotypes Number 
of flies 
Mean 
survival Days 
P-value 
(Bonferroni 
correction) 
compare to 
control 
Significance 
Ddc-Gal4;UAS-park-
RNAi;UAS-lacZ 
295 46 N/A N/A 
Ddc-Gal4;UAS-park-
RNAi;UAS-CG34126EY 
305 54 <0.0081 yes 
Ddc-Gal4;UAS-park-
RNAi;UAS-CG34126-
RNAiGD 
272 40 <0.0001 Yes 
Ddc-Gal4;UAS-park-
RNAi;UAS-CG34126-
RNAiKK 
295 52 <0.2151 No 
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Climbing analysis of the control and experimental lines in the UAS-park-RNAi 
model. 
Loss of locomotor power is one of the prominent symptoms of PD phenotypes as well as 
parkin RNAi mediated model of PD. So, it is worthwhile to detect the contributing role of 
CG34126 gene alteration in the park inhibition models. To investigate the probable effect 
in the dopaminergic neurons two inhibition lines UAS-CG34126-RNAiGD and UAS-
CG34126-RNAiKK and one overexpression line UAS-CG34126EY were crossed with the 
derivate line Ddc-Gal4;UAS-park-RNAi. 
CG34126 inhibition exacerbates climbing dysfunction in the UAS-park-RNAi 
model 
Inhibition of both CG34126 and park in the Drosophila showed a reduced climbing ability 
over time with the control flies (Figure 15). The 95% confidence interval for the flies 
produced from crossing of UAS-CG34126-RNAiGD with Ddc-Gal4;UAS-park-RNAi, UAS-
CG34126-RNAiKK with Ddc-Gal4;UAS-park-RNAi and UAS-lacZ with Ddc-Gal4;UAS-
park-RNAi were 0.03366 to 0.05601, 0.02466 to 0.03611 and 0.03010 to 0.04512 
respectively (Table 11). 
CG34126 overexpression rescues climbing ability in UAS-park-RNAi model 
Flies generated by crossing of UAS-CG34126EY and Ddc-Gal4;Uas-park-RNAi represented 
gradually better climbing ability compare to flies produced from crossing of control UAS-
lacZ and Ddc-Gal4;Uas-park-RNAi (Figure 15). 
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Figure 15. Climbing ability over time of flies with inhibition of park along with altered 
expression of CG34126 in Ddc-GAL4 expressing neurons. 
Inhibition of UAS-CG34126-RNAiKK and UAS-CG34126-RNAiGD directed by Ddc-
Gal4;UAS-park-RNAi decreased climbing ability over time compared to the control lacZ 
as obtained by non-linear fitting of the climbing curves and analyzing at 95% confidence 
intervals (P<0.05). But co-expression of UAS-CG34126EY and park-RNAi had significant 
effect in increasing locomotor ability compared to the control. Error bar represents standard 
error and n=50. 
Table 11: Comparison of climbing ability of flies with inhibition of park along with 
altered expression of CG34126 in Ddc-GAL4 expressing neurons by (Mental-Cox) 
Log-rank test. 
Genotypes Standard error 95%CI R square P value Significance 
Ddc-Gal4;UAS-
park-RNAi;Uas-
lacZ 
0.003850 
 
0.03010 to 
0.04512 
 
0.8008 
 
  
Ddc-Gal4;UAS-
park-RNAi;UAS-
CG34126EY 
0.004973 
 
 
 
0.03880 to 
0.05754 
 
 
0.8077 
 
 
<0.0383 
 
Yes 
Ddc-Gal4;UAS-
park-RNAi;UAS-
CG34126-RNAiGD 
0.005894 
 
 
0.03366 to 
0.05601 
 
 
0.7432 
 
 
<0.0480 
 
Yes 
Ddc-Gal4;UAS-
park-RNAi;UAS-
CG34126-RNAiKK 
 
0.003067 
 
 
0.02466 to 
0.03611 
 
 
0.7966 
 
 
<0.0366 Yes 
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Table 12: Summary of longevity and climbing over time results 
Lifespan Analysis 
Different genotypes 
of CG34126 
D42-GAL4 Ddc- GAL4 TH-GAL4 
Overexpression No change Decreased lifespan No change 
Inhibition RNAiGD Decreased lifespan Decreased lifespan Decreased lifespan 
Inhibition RNAiKK No change No change No change 
Climbing Analysis 
Overexpression No change Decreased 
climbing ability 
No change 
Inhibition RNAiGD Decreased 
climbing ability 
Decreased 
climbing ability 
Decreased 
climbing ability 
Inhibition RNAiKK Decreased 
climbing ability 
Decreased 
climbing ability 
Decreased 
climbing ability 
Different lines of CG34126 crossed with Ddc-GAL4/CyO; UAS-park-RNAi/TM3. 
Lifespan Analysis 
Overexpression  Increased lifespan  
Inhibition RNAiGD  Decreased lifespan  
Inhibition RNAiKK  No change  
Climbing Analysis 
Overexpression  Increased 
climbing ability 
 
Inhibition RNAiGD  Decreased 
climbing ability 
 
Inhibition RNAiKK  Decreased 
climbing ability 
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Discussion 
 
Parkinson Disease (PD) is initiated by a variety of genetic and environmental 
factors with an age-dependent demise of dopaminergic neurons, often associated with the 
aggression of the α-synuclein protein, is a common pathological condition (Botella et al., 
2009). There are many cellular processes such as mitochondrial dysfunction, oxidative 
stress, endo-lysosomal dysfunction, Golgi body dysregulation, and dysregulation of 
protein-trafficking that contribute to the symptoms of PD. Internal functions of the 
mitochondria modify non-functional proteins or degrade damaged protein. Interestingly, 
the ubiquitin-proteasome system has control over mitochondrial functionality and their 
mutual interaction is linked to PD (Franz et al., 2015). The gene selected for the study, 
UHRF1BP1L, has been shown to interact with mitochondrial dynamics by diminishing its 
number in affected neurons with altered morphology (Jansen et al., 2017). The 
UHRF1BP1L protein shares the Chorein-N domain with VPS13, which is a membrane 
trafficking protein. It might play an important role in both the integral surveillance of 
mitochondrial mechanisms and protein degradation. The UHRF1BP1L homologue 
CG34126 in Drosophila has not been extensively studied to observe ectopic expression. 
This study aimed to examine various aspects of the Drosphila melanogaster homologue of 
UHRF1BP1L. CG34126 was overexpressed and inhibited in dopaminergic, motor, and 
other neurons of Drosophila  melanogaster to determine its effects on cell death and growth 
which eventually contribute to longevity, locomotor ability, and eye development to 
recapitulate the phenotypic symptoms of PD.   
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Sequence alignment of human UHRF1BP1L and its homologue CG34126 in flies 
was carried out using the bioinformatics tool to identify similarity and identity. These two 
sequences showed more than 26.5% identity and 41.9% similarity in their amino acid 
sequences and they share the conserved domain Chorein-N and VPS13, indicating that 
Drosophila melanogaster CG34126 is closely related and a functional homologue to 
human UHRF1BP1L. Alignment of Drosophila CG34126 and human UHRF1BP1L with 
three invertebrate and vertebrate species further reinforces the evolutionary conservation 
of amino acid sequences. Same domains Chorein-N and VPS13 are well conserved among 
all the seven different protein sequences. The full-length VPS13 protein is a 
transmembrane protein with a presumed role in vesicle-mediated sorting and intracellular 
protein transport and it has a Chorein-N domain (Velayos-Baeza et al., 2004). Recent 
studies show that VPS13C regulates lipid trafficking between the endoplasmic reticulum 
and other membranous organelles. Dysfunction of lipid homeostasis due to mutation of 
VPS13C likely show clinical manifestations in patients with Parkinsonism (Kumar et al., 
2018). As the Chorein-N domain has been noted in both UHRF1BP1L and VPS13C protein 
(Mizuno et al., 2007) and its presence likely indicates that UHRF1BP1L has lipid transport 
modules alongside protein trafficking, which could affect PD pathology in a similar manner 
to VPS13C. However, another VPS35 protein has been linked to early-onset Parkinsonian-
pyramidal syndrome due to an impairment of endosome-to-Golgi retrieval of membrane 
proteins  (Zimprich et al., 2011b; Vilariño-Güell et al., 2013). It can be inferred that 
CG34126 plays a role in protein transferring dysfunction in PD. Furthermore, 
bioinformatic analysis was carried out to investigate the relationship between CG34126 
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protein and human UHRF1BP1, which is the only paralogue of human protein 
UHRF1BP1L. Alignment of human UHRF1BP1 and Drosophila CG34126 showed that 
the evidence of the conservation, such as 26.7% identical and 42.5% similar in amino acid 
sequence and is highly conserved in the Chorein-N and VPS13 domains. This indicates 
that similar to UHRF1BP1L, CG34126 is closely related to UHRF1BPI. Pairwise sequence 
alignment of human and fly demonstrated FNIII, ID/GR, and CC domains were conserved 
within the same amino acid sequences of both proteins, though these domains were not 
identified in fly by the CDD and Pfam. Two available domains, Chorein-N and VPS13, in 
both species showed more than 50% similarity, which validates the study of PD in the fly 
genes. Moreover, the presence of these two domains reinforce the protein trafficking role 
of CG34126 in PD pathogenesis. 
 
Genetic expression studies have extensively used the Drosophila eye to study of 
neurodegeneration because of the conservation of key signalling pathways between human 
and fly, and the ease of quantifying degeneration of photoreceptor neurons associated with 
each ommatidium. In Drosophila melanogaster, eye development is tightly controlled 
during the organization of the ommatidial array (Thomas & Wassarman, 1999). The eye 
consists of specialized structures called sensory bristles, that provide the opportunity for 
neurogenesis examination and for detection of even slight abnormalities (Baker, 2001). 
Reduction in the number of ommatidia, bristle and ommatidia area suggests a reduction in 
cell number during eye development. Reduction of cell number can occur through either 
increased cell death, or decreased cell proliferation (Kramer & Staveley, 2003). 
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Examination of both reduced and increased levels of CG34126 in the Drosophila eye were 
carried out using the transgenic eye tissue-specific GMR-Gal4, and the characteristics were 
analysed to identify the effects of altered gene expression. Directed overexpression and 
inhibition of UHRF1BP1L homologues in the eye showed no significant difference from 
the control, when compared for ommatidia or bristle numbers. Inhibition or overexpression 
of CG34126 did not alter the normal development of the eye and seems to have a limited 
role in neurodevelopment under normal cellular conditions or other factors contribute to 
this counterbalancing effect.  In a recent study that introduced a number of new PD 
candidate genes (Jansen et al., 2017), α-synuclein-induced retinal degeneration and 
screening assay in Drosophila; they did not observe significant retinal pathology in α-
synuclein null flies directed by Rhodopsin1-GAL4 but when the transgene was induced by 
α-synuclein it showed retinal degeneration with synergistic effects. It did not show any 
neuro development in the eyes of CG34126 regulated fly, but experiment with derivative 
flies or α-synuclein induced flies might show the expected PD phenotypes. 
 
Patient of PD commonly suffered from early death as well as other PD  symptoms 
(Forno, 1996). In these studies, I have detected that the inhibition of CG34126 of via RNA-
interference in flies directed by D42-Gal4, Ddc-Gal4 and TH-Gal4 have a deleterious 
effect on the survival rate compared to control, which is characteristic of PD-like 
phenotype. Same type of results has been observed in previous ageing analysis of flies, 
where due to the loss-of-function of park, flies showed shortened lifespan alongside 
reduced climbing ability and degeneration of DA neurons compared to the control (Greene 
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et al., 2003; Whitworth et al., 2005). Similarly, a decrease in nutcracker/Fbxo7 expression 
directed by Ddc-Gal4 caused a significant reduction in mean lifespan of flies (Merzetti et 
al., 2016). It may be possible that suppression of CG34126 creates inhibition in the normal 
function of the dopaminergic and motor neurons, and as a result the experimental flies died 
earlier than the control. However, the inhibition line UAS-CG34126-RNAiKK did not 
demonstrate any significant changes to the lifespan. Overexpression of CG34126 had no 
significant role in the ageing process except for the flies expressed under 3,4-
dihydroxyphenylalanine (DOPA) decarboxylase gene promoter Ddc-GAL4, which have a 
shorter lifespan compare to the control.  Any previous experiment has not been carried out 
in a longevity assay associated with UHRF1BP1L homologue in flies, therefore the exact 
reason for this reduction in lifespan due to inhibition and overexpression of CG34126 is 
unclear. An increase in programmed cell death or a decrease in cell growth during 
development, coupled with selective apoptotic death of these DA neurons due to altered 
expression of CG34126, may be the contributing factor which ultimately decreased cellular 
protection and survival of the cell and thereby decreased survival rate of the fly. 
Dopaminergic neurons may die as a result of apoptosis in PD (Lev et al., 2003). Exploration 
of the role of cell survival signalling in the selective loss of dopaminergic neurons in 
Drosophila may provide further insight into the molecular basis of PD. 
 
Locomotor disorder is one of the dopaminergic neuron-associated characteristics 
of PD. As the transgenic flies recapitulate some of the prominent features of PD, such as 
the degeneration of DA neurons and the age-dependent loss of locomotor capability, 
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movement analysis was conducted to determine the effect of CG34126 on climbing ability 
of Drosophila over time. Climbing ability acts as a key indicator of phenotypic expression 
of a particular gene in DA neurons. Analysis of climbing to determine the phenotypic 
effects of overexpression and inhibition of genes, especially to recuperate the α-synuclein 
induced PD phenotypes have been conducted many times (Feany & Bender, 2000; 
Haywood & Staveley, 2006; Todd & Staveley, 2008). Aucluck at el., (2002), used the UAS-
GAL4 system to regulate transgenic expression of the Chaperone Hsp 70 using the Ddc-
Gal4 line in flies and found that direct expression of the Hsp70 mitigated dopaminergic 
neuronal loss related with α-synuclein in flies and inhibition of Hsp70 promoting α-
synuclein induced neurodegeneration. In another transgenic experiment, it has been 
speculated that loss-of-function of Drosophila orthologue of human LRRK led to severe 
locomotor abnormality (Lee et al., 2007). In my experiment, I observed that suppression 
of both inhibition lines of CG34126 in flies with the three gene promoter Ddc- Gal4, D42-
Gal4, and TH-Gal4 caused a noticeable reduction in locomotor ability over time compared 
to control flies. Similar observations have been noticed by Feany & Bender, (2000), where 
the flies were unable to move upward beyond the first section of the climbing apparatus at 
the very end of their lives. CG34126 is producing similar effects in Drosophila as to what 
would be expected by knockdown of UHRF1BP1L. This may be because loss-of-function 
of CG34126 negatively affects the dopaminergic neurons’ surveillance and defects in 
mitochondrial biogenesis by interfering protein transport. There were no changes in 
climbing ability for the overexpression of CG34126 in flies except in those, who were 
controlled under the Ddc-Gal4 transgene, which showed a decreased in movement ability 
79 
 
with progression of time. It is apparent that one inhibition line has more severe ageing 
effects compare to another inhibition line, but both lines represented decline in the climbing 
ability over time. The inhibition of CG34126 under the control of DA and motor neurons 
result in short lifespan and impaired locomotor function, phenotypes that are strongly 
relatable to the Drosophila models of PD. Flies have phenotypes that are consistent 
modelling PD in Drosophila through alteration of CG34126. 
Parkin takes part in protein ubiquitination through affecting the function of the 
ubiquitin-ligase enzyme, and mutation of it is involved in abnormal protein aggregation 
causes decease of neuronal cell (Shimura et al., 2000). Mutual interaction of PINK1 and 
parkin maintains the mitochondrial integrity. Overexpression of mitochondrial fission 
regulating gene in Drosophila rescues the phenotypes of muscular defects and 
mitochondrial dysfunction in park mutant flies (Deng et al., 2008). In our study, co-
expression of park-RNAi and CG34126 overexpression under the control of dopaminergic 
Ddc-Gal4, resulted in an improved climbing ability compared to the control. Moreover, 
overexpression of CG34126 positively acted to retrieve survival ability in park RNA-
interference flies. Similarly, the inhibition of porin along with the overexpression of Buffy 
in the DA neurons results in the suppression of the age-dependent loss in climbing ability 
and survival rate (M’Angale & Staveley, 2016b). In another experiment, it was found that  
overexpression of Pink1 rescued the premature loss of climbing abilities induced by α-
synuclein (Todd and Staveley, 2008). In this experiment when CG34126 was 
overexpressed in dopaminergic neurons, the flies lived and climbed longer than the control. 
It recuperates both climbing and survival ability of park RNA-interference flies. It can be 
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predicted that overexpression of CG34126 may have positive role in maintaining 
mitochondrial dynamics, cell growth, and overcome the toxicity produced by park 
suppression. On the other hand, co-inhibition of both genes park-RNAi and UAS-CG34126-
RNAiGD in DA neurons under the dopaminergic neuron-specific transgene deteriorated not 
only the movement ability but also the lifespan of transgenic flies. Another inhibition line 
UAS-CG34126-RNAiKK showed normal lifespan with decreased locomotor power when 
crossed with park-RNAi regulated by same Ddc-Gal4 transgene. Inhibition of both gene 
CG34126 and park in the flies demonstrated a significant reduction in climbing and 
survival ability and indicated that reduced level of park and CG34126 expression might 
have detrimental effects, which is relatable to the symptoms of PD affected patients. 
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Conclusion 
 
Characterization of the Drosophila melanogaster homologue of UHFR1BP1L has 
been done through the overexpression and inhibition of the CG34126 gene in eye 
development, longevity and climbing ability along with bioinformatic analysis. 
UHRF1BP1L protein is well conserved in functional protein trafficking domains of both 
human and Drosophila. However, this protein is not highly conserved at the amino acid 
level due to the evolutionary genetic divergence between vertebrates and invertebrates but 
conserved in their respective groups. Loss-of-function of CG34126 leads to reduced 
longevity with climbing and gives a model of PD. Gain-of-function does not provide any 
prominent PD symptoms but it rescues the parkin RNAi model of PD by increasing both 
longevity and locomotor ability. Further cellular and molecular study and interaction of 
UHRF1BP1L and its homologue CG34126 with others PD genes such as α-synuclein, 
PINK1, and VPS13C can be carried out for the manipulation of drugs that possibly  function 
better in the PD affected patients.  
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